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Hypofractionated dose painting radiotherapy for prostate adenocarcinoma (J. Chan) 
For prostate adenocarcinoma, standard radiotherapy delivers a homogeneous dose 
to the whole organ; higher doses improve biochemical control but increases toxicities. Dose 
painting with simultaneous integrated boost (SIB) to the dominant intra-prostatic lesions 
(DILs) may improve outcomes without increased toxicities. There is only one published study 
(of 28 patients) on prostate dose painting using the moderately hypofractionated UK 
standard schedule 60 Gy/20 #/4 weeks (with boost to 68 Gy)(Onjukka et al. 2016), and dose 
painting with boosts to both prostate and pelvic lymph nodes using this dose fractionation 
schedule have not previously been described. To identify boost volumes, visible tumour 
lesions (DILs) are primarily delineated using multiparametric MRI. An alternative may be 
choline PET/CT; in this thesis, we used the tracer 18F choline which was available during the 
time of patient recruitment. 
This thesis will describe the dynamic tracer uptake profile of 18F choline and the effect 
of bicalutamide on it; the difference in boost volume using either MRI or 18F choline PET 
alone and compare this to the combination of MRI and 18F choline PET/CT with and without 
bicalutamide; and the feasibility and tolerability of dose painting with a moderately 
hypofractionated schedule. This involves analysis of imaging, radiotherapy plans, and follow 
up of patients within the pilot study and the BIOPROP20 trial. Briefly, patients were offered 
to take part in the research if they had newly diagnosed intermediate or high risk 
histologically confirmed prostate adenocarcinoma staged as T2a-4, N0, M0, with pelvic nodal 
risk of 15% - 40% (Roach formula). In terms of planning aims, the radiation dose to the 
prostate was 60 Gy with a boost to the DIL of 68 Gy, and if treated, the pelvic nodes was 45 
Gy with a boost to involved nodes of 50 Gy. 
Dynamic imaging with 18F choline PET/CT showed that tracer uptake was higher in 
tumour compared to benign tissue. Bicalutamide reduced whole prostate volume by 17%. If 
patients had PET/CT scans after 2-3 months of bicalutamide, there were no DILs on the 90 
minutes static scan for around a third of patients, and the size of the detected DILs were 
significantly smaller when compared to corresponding MRI. Median DICE between MRI and 
PET/CT boost volumes were 0.51 and 0.61 when defined by SUVmax 60% threshold method 
and visual method respectively. If the final boost volume was defined by the combination of 
MRI and PET volume, the additional use of PET/CT significantly increased the overall boost 
volume when compared to using MRI alone. 
It was possible to increase the dose to the prostatic boost volumes to 68 Gy for most 
patients; in some patients with boost volumes close to the OARs or large boost volume, the 
boost dose was lower to achieve the dose constraints for normal tissues (rectum, bowel, 
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bladder and urethra). The treatment was well tolerated with acute toxicity peaking at week 
6 at the latest and with acceptable late toxicity. 
 In conclusion, the addition of 18F choline PET/CT to MRI for prostate dose painting 
radiotherapy planning can significantly alter the boost volume, and PET/CT should be 
performed without bicalutamide. Planning and delivery of dose painting with a moderately 
hypofractionated schedule are both feasible and clinically acceptable regarding toxicity. The 
presented planning protocol has been used for a multicentre, randomised Phase III trial 
(PIVOTALboost); this should demonstrate any long term toxicity and clinical benefits of dose 




 Prostate Cancer 
1.1.1 Epidemiology, staging and principals of treatment 
Since the early 1990s, incidence of prostate cancer has increased by 44% in the UK, in part 
due to prostate specific antigen (PSA) screening(1). Currently, it is the commonest cancer in 
men in the UK, with 47,200 new cases in 2015. One in 8 men will be diagnosed with it in their 
lifetime, and most will be at an early stage with organ-confined disease(2). Approximately 
70% of prostate cancers arise in the peripheral zone with 30% in the central gland(3), and 
disease may be unifocal or multifocal within the prostate(4). Recognised risk factors include 
increasing age, ethnicity (Afro-Caribbean heritage) and family history(5). 
Disease assessment involves clinical staging (digital rectal examination (DRE) and 
multiparametric magnetic resonance imaging (mpMRI)), PSA levels, and histology (Gleason 
score and grade group)(2). Imaging of the prostate will be discussed in detail in subsequent 
sections of this introduction. PSA is a serine protease produced by both prostate epithelial 
cells and neoplastic prostatic cells. Therefore it can be raised for benign conditions such as 
benign prostatic hypertrophy (BPH) and prostatitis, or malignant conditions such as prostate 
adenocarcinoma. The Gleason score grades prostate adenocarcinoma based on degree of 
glandular differentiation and overall pattern of growth. The overall score is the summation 
of the primary and secondary patterns, ranging from 6 to 10, and gives a grade group of 1 to 
5(6). These three factors are used to aid decision making by risk stratifying the disease to 
determine its overall clinical significance. A commonly used risk classification system is by 
NCCN as defined in Appendix 8.1(7). Although there are proposals for additional 
investigations that would further guide management decisions, such as by using novel 
biomarkers and risk calculators in the pre-biopsy setting to predict a positive prostate 
biopsy(8), and by molecular testing for men considered suitable for active surveillance with 
low risk and >10 years life expectancy (9), they are not currently in routine clinical use. 
With localised disease, treatment aim is for cure whilst minimising toxicity. For intermediate 
and high risk disease, the two established modalities are surgery (radical prostatectomy +/- 
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lymph node dissection) and radiotherapy (external-beam radiotherapy (EBRT) +/- 
brachytherapy, with hormone therapy). As will be discussed in more detail later, many of 
these patients who have radical radiotherapy achieve disease control for several years (e.g. 
CHHiP showed that 91% of patients receiving 60Gy were biochemical or clinical failure free 
at 5 years(10)). Prostate cancer and its treatment are the leading cause of cancer years lived 
with disability. Therefore, consideration of survivorship issues including both acute and late 
toxicity is important. 
Following radical treatment, patients are primarily assessed by clinical and biochemical 
monitoring. Biochemical endpoints involving PSA are used as surrogates for treatment 
efficacy, which can take several years to determine owing to the often slow natural history 
of the disease(6). Currently, biochemical failure after radiotherapy is defined by the Phoenix 
criteria: PSA rise of 2 ng/ml over the nadir(11). 
 Imaging in prostate cancer 
1.2.1 MRI 
MRI is currently recognised as the gold standard imaging modality for pre-treatment local 
staging of prostate cancer. It allows accurate identification and assessment of the local 
extent of disease, which aids selection of appropriate treatment strategies, without the use 
of ionising radiation or invasive procedures(12, 13). The technology has improved over time. 
Use of endorectal coils had allowed improved signal-to-noise ratio resulting in higher 
resolution images but with some image distortion(4). Modern MRI scanners do not require 
endorectal coils to provide highly detailed anatomy as they use higher field strength MRI 
imagers (e.g. 3Tesla (3T)) and multi-channel phased array surface coils(12, 13). An important 
advantage of using imaging is that TRUS guided biopsies mostly assess the peripheral zone 
only, which can lead to diagnostic errors with false negative results(4, 11). 
MRI can perform multiple imaging sequences to assess different aspects of tumour 
biology(14). mpMRI uses a combination of high resolution anatomical (primarily T2w) and at 
least two functional (such as DWI, dynamic contrast enhanced (DCE) and magnetic 
resonance spectroscopy (MRS)) pulse sequences(6, 13). These individual sequences have 
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inherent strengths and weaknesses, which allows them to complement each other. Hence 
overall disease interpretation relies on combining these MRI sequences which improves 
accuracy of detection and localisation of tumours(4). 
T2w MRI provides superior soft tissue contrast of the prostate(15-18). Normal tissues often 
exhibit high-signal intensity, whilst malignant tissues have low-signal intensity due to loss of 
glandular morphology. However low-signal intensity is not specific to cancer, and can 
indicate benign conditions such as post-biopsy haemorrhage, prostatitis, BPH, and post-
treatment changes. Interpretation of the transitional zone is more difficult than the 
peripheral zone due to the presence of BPH, although BPH are generally well defined and 
round. T2w can determine whether tumour is confined to the prostate or whether there is 
extra-prostatic extension(19). In the latter, imaging can show the tumour directly extending 
outside the prostate and cause features such as asymmetry of the neurovascular bundle or 
prostate rotations. It can also determine seminal vesicle invasion, identified by low signal on 
a background of high signal normal tissue, although benign conditions of the seminal vesicles 
can again complicate interpretation such as calculi, clots or atrophy. Hence T2w sequencing 
is important to determine T-staging. Differing sensitivity and specificity values of T2w 
imaging have been reported due to differences in patient selection (affecting tumour 
characteristics) and the use of different standard comparators (e.g. biopsy, surgical 
specimens). For instance, T2w imaging alone by a 3T machine could identify large tumours 
(> 1 cm in diameter) with 80 – 90% accuracy, whilst smaller tumours had a lower 
accuracy(13). 
DWI MRI relies on the random diffusion of water molecules within the extracellular space, 
and follows tissue planes and natural barriers(13, 20). This Brownian motion is restricted in 
regions of high cellular density and extracellular disorganisation, such as malignant 
tissues(14). By applying varying strengths of external magnetic gradients (b-values), moving 
water molecules acquire varying phase shifts according to the amount of motion, allowing a 
quantitative estimate of the overall water diffusion, which can create an apparent diffusion 
coefficient (ADC) map. In the peripheral zone, tumours are generally hyper-intense on DWI 
MRI and hypo-intense on ADC maps when compared to normal tissue. In the transitional 
zone, interpretation can again be more difficult due to BPH, which are also hypo-intense on 
ADC maps. The addition of DWI to T2w imaging improves sensitivity and allows better 
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detection of peripheral zone tumours(13). DWI is limited by poor spatial resolution and 
susceptibility to artefacts such as bowel gas(13). 
DCE MRI assesses the perfusion and permeability of the microvasculature by using 
intravenous gadolinium-based contrast(14, 21). It involves rapid T1w imaging before, during 
and after IV contrast. Tumours have disorganised angiogenesis, which are highly permeable, 
generally resulting in more rapid and intense enhancement as well as faster washout. DCE is 
often interpreted by visual assessment and has a high sensitivity to detect malignant lesions 
and assess grade(13). As well as for preoperative staging including seminal vesicle invasion, 
DCE is particularly useful for identifying recurrence following primary treatments such as 
radiotherapy and focal ablation as they can cause anatomical and functional changes to 
which other sequences are susceptible. Limitations to DCE include poor spatial resolution 
and malignant tissue, especially if small and low grade, in the transitional zone have a similar 
enhancement to benign conditions such as BPH and prostatitis. 
MRS is a functional imaging sequence, which identifies the relative concentrations of cellular 
metabolites such as choline and citrate(22). Choline is involved in membrane synthesis and 
the quantity is expected to be raised with cellular proliferation (14). Malignant tissues have 
high levels of choline, and low levels of citrate. MRS alone has been shown to predict cancer 
aggressiveness, and the addition of MRS to T2w MRI can increase specificity(13). However it 
also has poor spatial resolution and is technically challenging to perform. Interpretation of 
the imaging requires significant experience with variable results in multicentre studies when 
compared to other sequences. As a result, MRS is not often performed as part of prostate 
mpMRI. 
In general, T2w allows optimal soft-tissue imaging and anatomically-defined tumour 
volumes to be identified(14), whilst the other functional sequences can confirm the 
detection of clinically significant higher grade intra-prostatic tumours. Overall, mpMRI has 
sensitivity and specificity values of 86% and 94% respectively for identifying lesions > 0.5 ml 
when compared to radical prostatectomy samples(13). In routine clinical practice, the 
Prostate Imaging – Reporting and Data System (PI-RADS) V2 framework is used to identify 
clinically significant prostate cancer on mpMRI, and this usually involves T2w and DWI 
sequences(23). PI-RADS V2 was able to correctly identify above 94% of cancer of ≥ 0.5 ml, 
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but was limited for Gleason ≥ 4+3 tumours of ≤ 0.5 ml size(24). An advantage of improved 
accuracy in detecting larger, higher grade tumours in the context of dose painting 
radiotherapy is that these lesions would likely benefit from dose escalation boosting, whilst 
smaller, lower grade tumours are likely to receive a sufficient dose without dose escalation 
boosting(11, 25). 
For general radiotherapy planning, MRI can aid the delineating of structures that are more 
difficult to identify on the planning CT scan, such as prostatic apex which can reduce penile 
bulb dose and lead to reduced toxicity(26). It also allows more accurate delineation of the 
whole prostate, and has been found to reduce the total prostate clinical target volume (CTV) 
by 30% as well as inter-observer variation(27, 28). The mpMRI can be co-registered to the 
planning CT scan by using intra-prostatic fiducial markers as the reference landmark(29). 
For identifying intra-prostatic lesions for dose escalation boosting, the evidence available are 
mostly from single institution studies and so are difficult to extrapolate to other institutions 
with different scanners. Also the studies primarily used pathology as the reference, and so 
limited the evaluation of this imaging modality to the specific patient population suitable for 
prostatectomy i.e. lower risk disease with lower disease burden when compared to the 
population suitable for radiotherapy. A recent study found mpMRI had sensitivity and 
specificity of 70% and 82% for detecting prostate cancer on histology(30).  Another study 
showed that mpMRI based delineating achieved 44 – 89% tumour coverage (smallest lesion 
was 0.56 cc)(31). With estimated co-registration errors of 2 – 3 mm, a 5 mm margin improved 
this to 85-100%. Overall, mpMRI is able to guide tumour deleating for dose painting 
radiotherapy. 
1.2.2 PET/CT 
PET scanning is a functional and molecular imaging technique which uses a tracer (a positron-
emitter bound to a targeted molecule) to assess the distribution of the targeted molecule 
(14). The tracer indirectly emits a pair of gamma rays. These are detected and a three 
dimensional reconstruction of the uptake can be created. Most modern machines have a CT 
scanner integrated with the PET scanner, allowing corresponding anatomical and functional 
information to be collected. Depending on the tracer characteristics, uptake can reflect 
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several biological processes including hypoxia, proliferation, metabolic activity, and 
perfusion(14). PET imaging is often more sensitive than MRI, but has a comparatively low 
spatial resolution(13). 
Several tracers have been investigated for prostate cancer. However unlike MRI, there have 
not been large multicentre studies, which is partly due to scarcity of on-site cyclotrons at 
clinical trial research centres. Also comparing the accuracy of different tracers is difficult as 
institutions often use differing imaging protocols and image analysis methodologies(14). 
The most commonly used compound in general oncology is 18F fluorodeoxyglucose (FDG), a 
glucose analogue which is an indicator of glycolysis and metabolic activity, and is 
preferentially taken up more in malignant than benign tissue due to upregulation of GLUT-1 
glucose transporters and increased glycolytic activity in cancers (Warburg effect)(13, 14). 
However in prostate cancer, it has been shown to perform poorly as lower grade disease do 
not rely on glycolysis and so have low levels of GLUT-1 expression related to inherently 
slower growth(6, 13, 32). Also 18F FDG is not specific to malignancy but is also taken up in 
BPH and prostatitis(12, 13). 
11C acetate is taken up into the cell membrane of prostate cancer cells and is excreted 
primarily by the pancreas, making it suitable for prostate imaging. However 11C has a short 
half-life of 20 minutes and so is only useful for centres with an on-site cyclotron. It has a 
higher sensitivity when compared to 18F FDG, but it has a lower sensitivity and specificity 
compared to mpMRI (62% and 80%, vs. 82% and 95%)(13). 
Choline is a cell membrane component, which is required by proliferating cells. It is 
transported into cells by choline kinase which is upregulated in prostate cancer (14). They 
are then phosphorylated and incorporated into the lipid cell membrane. 11C choline and 18F 
choline tracers have been used. The former has low urinary excretion, which is beneficial for 
prostate imaging, but a short half-life. The latter has a higher urinary excretion, but a longer 
half-life of 110 minutes(32). Studies of either tracer have often used different imaging 
protocols (such as tracer doses and tracer uptake time before scanning) and image analyses 
(such as using histopathology or MRI as the reference standard; correlation methods by 
laterality, sextants or octants; and determining imaging as positive for malignancy by visual 
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analysis or differing SUV thresholds), and have shown conflicting results (Tables 1-1, 1-2, 1-
3). More studies have been performed for 11C choline than 18F choline. When comparing 11C 
choline with histopathology, reported specificity ranges from 42.6% to 87.0%, and accuracy 
ranges from 59.6% to 84.0% (Table 1-1). When comparing 18F choline with histopathology, 
reported specificity ranges from 76% to 90%, and accuracy ranges from 72% to 81% (Table 
1-3). When correlating both choline and MRI with histopathology, 18F choline has been 
shown in one study to perform better than MRI (accuracy 81% vs. 60% respectively; Table 1-
4). This used a comparatively long tracer uptake time before PET scanning (static scanning 
at 48 minutes and 71 minutes after tracer injection)(33). Current evidence suggests that 
accuracy of 18F choline PET is improved by increasing the tracer dose and by delayed 
scanning, but there is a lack of consensus on scanning protocols and the optimal techniques 
remain unclear(14). 
Choline PET has been used to investigate intra-prostatic dose escalation radiotherapy 
planning. In a radiobiological modelling study, Chang et al. used 11C choline with a tracer 
uptake time of over 60 minutes and SUVmax threshold of 60 and 70%. In planning and 
treatment studies, Pinkawa et al. used 18F choline with a tracer uptake time of over 60 
minutes and a threshold defined by a tumour-to-background SUVmax ratio of more than 
2(33). 
More recently, results from 68Ga-labelled PSMA ligand PET imaging have been very 
encouraging and can now be used in routine clinical practice for patients with suspected 
recurrent following previous radical therapy in the UK. In the primary staging setting, PSMA-
PET led to upstaging of disease and therefore treatment modification in 21% of patients(34, 
35). PSMA-PET can detect intra-prostatic lesions in up to 95% of cases, and combining it with 
mpMRI can improve coverage of cancer on histology by providing complementary 
information(30, 36). Dose painting radiotherapy planning using PSMA PET/CT and mpMRI 
with dose fractionation of 2.0 to 2.2 Gy per fraction to the prostate is technically feasible(37). 
Other radionuclide tracers have been used for prostate cancer but with fewer published 
studies. 18F fluciclovine is a synthetic amino acid which undergoes increased uptake in 
malignant cells but also localises benign prostate hypertrophy nodules with similar avidity, 
and so its role in initial staging is not clear(38). 18F MISO, CuATSM and FAZA have been used 
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to image hypoxic regions of the prostate which may be more radio-resistant, and FLT has 
been investigated for analysing tumour repopulation rates (14). However evidence for their 
use in dose painting radiotherapy planning is limited. 
Limitations of PET imaging include spatial and temporal variability of the biological processes 
including perfusion, hypoxia and metabolic activity. With the former, these processes occur 
at a microscopic level and spatial resolution of individual voxels is generally poor, and so 
small lesions may not be detected due to partial voluming effects. With the latter, the 
reproducibility of imaging may be affected. Hence image analyses may be simplifying the 
various complex underlying processes(14). Currently, PET/CT for prostate cancer is primarily 
accepted for detecting recurrent disease as opposed to for primary staging, and in my thesis 
I will explore the value and additional benefits of adding choline PET to the staging and 
radiotherapy planning compared to mpMRI only.
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Table 1-1 Studies correlating 11C-choline PET and histopathology (All used PET/CT except Chang et al. who used PET and transmission scanning) 
¤scan sequences were static except Chang et al. which was dynamic, * only pts who had radical prostatectomy in the study are included in this table (of these, 7 
of 19 patients had preceding hormone therapy),  † Unclear if contains patients from Farsad et al.,  ‡ All pts received chemotherapy before prostatectomy, n = 

















Sensitivity Specificity PPV NPV Accuracy 
Van den Bergh 
et al.(39) 
49 octants 2 min 
740 to 
1000 
over 5 min 




77.4% 44.9% ND ND 61.1% 
Souvatzoglou 
et al.(40) 
43 laterality 5 min 
682 ± 
75 







79% of pts 









over 3 - 5 
min 
mean 3.3 




value of 4.9 ± 
1.8 or variable 
threshold 
SUVmax of 75.6 
± 14% 
ND ND ND ND ND 
Giovacchini et 
al.(42)* 
19 sextants 5min 370 over 4 min ND 
Threshold of 
SUVmax 2.5 





36 sextants 5 min 
370 to 
555 














over 5 min ND 
Visual analysis 
by sextants 
65.6% 84.2% 87.7% 58.8% 72.5% 
Testa et 
al.(45) 
26 sextants 5 min 
370 to 
555 
over 5 min ND 
Threshold of 
SUVmax 2.9 
72% 65% ND ND ND 
Piert et al.(46) 14 
using ex vivo 
MR and block 
face 
photography 
5 min 700 over 7 min 
0.03 - 12.6 
cm3 
Not specified, 







ND ND ND ND ND 
Reske et 
al.(47) 
26 36 segments 5-10 min 
1112 ± 
131 
over 3 min 




81% 87% 86% 83% 84% 
Chang et 
al.(48)‡ 
8 at voxel level Immediately 370 
over 60 
min 








Table 1-2 Sensitivity and specificity of 11C choline PET for identifying malignancy with varying SUVmax threshold values 
Author n 
Number of segments per 
prostate 
Total number of segments 
analysed 
SUVmax threshold Sensitivity Specificity 
Giovacchini et 
al.(42) 
19 6 114 2.5 71.6% 42.6% 
Reske et al.(47) 26 36 936 2.65 81% 87% 
Van den Bergh et 
al.(39) 
49 24 1,176 2.7 77.4% 44.9% 
Testa et al.(45) 26 6 156 2.9 72% 65% 






Table 1-3 Studies correlating 18F-choline PET and histopathology (all studies used 18F-fluorocholine except Hartenbach et al. who used 18F fluoroethylcholine) 
¤ study included combination of newly confirmed diagnosis and recurrent prostate cancer pts, 2 of the pts had preceding hormone therapy 
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Immediately (dynamic over 
10 min), then 48 min (static 
over 3 min), then 71 min 
(static over 6 min) 
3.3 
MBq/kg 




Immediate (dynamic over 15 
min), then 60 min (static over 
2.5 min) 




1 min (dynamic over 8 min) 
then 10 min (static over 4 
min) then 90-120 min if 
abnormal at 10 min (static 




Visual analysis performed 
only (highest SUV sextant 
had maximal tumoural 
infiltration) 




































49 octants 11C-choline 
2 min (static 






>  5 mm 
diameter 









than MRI  
Pinaquy et 
al.(53) 












ND 60% 76% 72% 69% 
SUVmax 
threshold 











26 sextants 11C-choline 
5 min (static 
























20 laterality 11C-choline 
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1.2.3 Pelvic lymph node staging 
Prostate adenocarcinoma can spread to the regional pelvic lymph nodes. Conventional CT 
relies on morphological appearances and, considering up to 80% of metastatic lymph nodes 
have a short-axis diameter of < 7 mm, has a low sensitivity of around 25%(6, 32). MRI with 
diffusion weighted imaging (DWI) also performs poorly, with a prospective study showing 
lymph node region-based sensitivity of 19% and patient-based sensitivity of 43%(56). 
Overall, up to 25% of patients with presumed node negative disease on standard pre-
operative staging scans are revealed to have metastasis on lymph node dissection(57). An 
alternative imaging modality which is not routinely used for lymph node staging is 
PET/CT(58, 59). The value of 18F choline PET/CT in initial staging is unclear, with sensitivity 
ranging from 56% to 67%, and PPV ranging from 40% to 98%(60). A large prospective study 
involving 210 patients with intermediate and high risk disease showed that 41 patients 
(19.5%) had histologically involved nodes, and the sensitivity, specificity, PPV and NPV of 18F 
choline PET were 56%, 94%, 40% and 97% (mean diameter of metastatic nodes was 10.3 
mm)(61). This relatively low PPV contrasts with another study involving 47 patients with 
intermediate and high risk disease which showed that sensitivity and PPV of 18F choline was 
56% and 98% (median size of metastatic nodes was 9.2 mm)(53). Another study involving 48 
patients with intermediate and high risk disease showed that sensitivity, specificity, PPV and 
NPV of 18F choline PET were 67%, 93%, 86% and 82%(62). 
In terms of pelvic lymph node regions that are at risk of metastasis, a mapping study of 
patients receiving extended pelvic lymph node dissection found that 81% of node positive 
patients had disease in the obturator and external iliac regions, 48% had disease in the 
internal iliac regions, and 37% had disease in the common iliac regions(63). Another surgical 
series show that internal iliac, external iliac, obturator, presacral, common iliac, and aortic 
bifurcation regions were involved in 35%, 26%, 25%, 9%, 3%, and 1% respectively of positive 
lymph nodes found in 34 patients(64). 
For patients who are node negative on clinical staging, various tools have been developed 
to predict the risk of lymph node metastases. The Roach formula [10 x (Gleason score – 6) + 
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PSA x 2/3] is well established, although a study found that it overestimated risk as it was 
established prior to use of PSA screening which has led to stage migration(65, 66). More 
recent tools based on contemporary patients are available, such as updated Partin, MSKCC, 
and Briganti nomograms(67-69). These newer tools try to incorporate a measure of tumour 
bulk, and accuracy of these three tools are broadly similar(70). Despite the availability of 
them, the Roach formula remains in use due to its ease and convenience. 
 Hormone therapy in prostate cancer 
Androgens bind to androgen receptors (AR), resulting in transcription of AR target genes that 
promote growth of normal and malignant prostatic tissue. Hormone therapy interferes with 
this process, causing accelerated apoptosis in normal, hyperplastic and dysplastic epithelial 
cells, leading to global glandular atrophy especially in the peripheral zone(6). The prostate 
gland volume is downsized by around 25 – 30%(27, 71). Furthermore, hormone therapy can 
improve outcomes by causing radio-sensitisation, improved oxygenation, and effects on 
micro metastases(72-74). There are two broad classes of non-surgical hormone therapy: 
LHRH agonists and anti-androgens(75). 
LHRH agonists bind to LHRH receptors located in the anterior pituitary gland, resulting 
initially in a testosterone surge that can cause a tumour flare. However as the physiological 
levels of LHRH is pulsatile, the prolonged stimulation of LHRH receptors causes their 
downregulation and resultant downstream testosterone reduction to castrate levels(75). 
Anti-androgens (such as bicalutamide) are competitive inhibitors of the AR and do not cause 
reduction in testosterone levels, but renders the circulating androgens ineffective(73). For 
short course of hormone therapy (6 months of treatment), bicalutamide is most often used. 
In the curative setting, hormone therapy is not used in isolation. This is supported by EORTC 
30891 and Lu-Yao et al. studies: comparing observation and primary hormone therapy alone 
in non-metastatic patients, there was no difference in survival(76, 77)(Table 1-5). 
When hormone therapy is used in combination with radical radiotherapy, no studies have 
directly compared the efficacy of LHRH agonist and antiandrogen, although studies 306 and 
307 compared bicalutamide and castration (including medical castration with goserelin) and 
34 
 
found that there was no difference in overall survival or time to progression at 6.3 years 
follow up, and that bicalutamide was better tolerated than castration(78). 
For early localised prostate cancer, there is little evidence to support the additional use of 
antiandrogens in addition to standard care. The SPCG-6 study showed that, when comparing 
standard care only and standard care with bicalutamide, there is no significant difference in 
progression free survival or overall survival in localised disease at 7.1 years follow up(79). 
For locally advanced prostate cancer however, SPCG-6 did show significant benefit with the 
addition of bicalutamide on top of standard care(79). This is confirmed by RTOG 85-31, RTOG 
86-10, EORTC 22863, and TROG 96.01(80-83). 
In terms of duration of hormone therapy, EORTC 22961 showed that 6 months was inferior 
to 3 years in locally advanced disease(84). Also when specifically looking at high risk patients 
including those with Gleason 8 – 10, RTOG 92-02 showed that long term treatment did 
confer a significant survival advantage over short term treatment(85). 
It should be noted that these studies used generally low radiation doses (< 70 Gy) compared 
to the modern era of dose escalation (> 70 Gy), where radiotherapy planning and delivery 
technologies have improved to allow conformal and IMRT planning resulting in higher doses 
delivered to the target volume whilst minimising doses to surrounding organs. Although 
there isn’t a prospective randomised control trial to determine whether the benefit of 
hormone therapy in RT is maintained in the setting of dose escalation RT, evidence still 
suggests that long course hormone therapy significantly improves survival for intermediate 
and high risk disease compared to short course hormone therapy, such as the DART01/05 
study where patients had 76 to 82 Gy delivered to the prostate and seminal vesicles(86-88). 
As well as survival advantages, it is important to consider the toxicity of hormone therapy in 
the context of a disease where prognosis is generally good following radiotherapy. Toxicities 
include fatigue, hot flashes, gynaecomastia, metabolic (increased serum lipids, decreased 
insulin sensitivity, increased subcutaneous body fat and obesity), musculoskeletal 
(osteoporosis, muscle loss), neurocognitive (depression, mood swings), and sexual 
function(19, 77, 89). There is conflicting evidence regarding association between long-term 
35 
 
castration deprivation therapy and cardiovascular disease. EORTC 22863 found no difference 
in cardiovascular mortality between radiotherapy alone and radiotherapy + goserelin (3 
years) group at 10 years follow-up. Furthermore, a meta-analysis combining 4,141 patients 
with unfavourable risk prostate cancer from eight prospective clinical trials found that the 
rate of cardiovascular death was not significantly different between patients given hormone 
therapy and those without (11.0% and 11.2%, p = 0.41)(90). However, analysis combining 
data from 1,372 patients from three prospective clinical trials found that 6 months of 
hormone therapy led to a shorter time to fatal myocardial infarction for those 65 years of 
age or older, but not in those below 65 years of age(91). This may therefore counteract the 
benefits of treatment in patients with cardiovascular morbidity (73, 75). Using anti-
androgens instead of LHRH agonists can lead to improved quality of life such as sexual 
interest and physical capacity, and is generally more tolerable(78). It reduces the risk of 
osteoporosis, hot flashes and impotence, but has risk of gynaecomastia, breast pain, 
diarrhoea and hepatotoxicity(73, 92). Therefore a balance between the treatment benefits 
and the impact on quality of life should be weighed for each individual patient(75, 93). 
In summary, there is evidence from multiple large randomised studies for the survival 
benefits of the addition of hormone therapy to conventional doses of radiotherapy in 
intermediate and high risk prostate cancer patients, and that longer duration of hormone 
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 Prostate Radiotherapy 
1.4.1 External beam radiotherapy techniques (IMRT, IGRT) 
External beam radiotherapy is a standard definitive treatment option for prostate 
cancer(94). It involves the use of a linear accelerator to produce megavoltage photons of 
between 4 and 20 MV energy(95). The primary objective of EBRT is to deliver a therapeutic 
dose to the target volume whilst minimising dose to benign neighbouring tissues, thereby 
achieving high tumour control probability and minimising normal tissue complication 
probability(20, 96). 
Over the last decades, EBRT planning and delivery methods have evolved with improving 
technological advancements. Modern treatment protocols use rotational IMRT (VMAT) or 
tomotherapy in conjunction with IGRT. Rotational IMRT involves the continuous delivery of 
dose during gantry rotation and multi-leaf collimator (MLC) movements. IMRT is able to 
generate steep dose gradients, and allows doses to conform closely to the treatment target 
and so greater sparing of the surrounding normal tissues and correspondingly reduced 
toxicity(4, 94). During the radiotherapy planning process, dose volume histograms (DVHs) 
are used to assess the dose delivered to the treatment targets and organs at risk (OAR). For 
the latter, dose constraints are applied during inverse planning to control dose to these 
surrounding critical structures. OAR include the rectum, bladder, bowel, femoral heads, 
penile bulb and urethra. Modern dose constraints are derived from well-established clinical 
trials such as MRC RT01, RTOG studies and CHHiP(97-100). Genito-urinary (GU) and gastro-
intestinal (GI) toxicities are the dose limiting toxicities in prostate radiotherapy, and 
complications can significantly reduce QOL(11, 96). 
Interfraction movement of the prostate can be large (> 1 cm) especially in the anterior-
posterior directions, and is due to variable filling of deformable organs surrounding the 
prostate, namely bladder and rectum(101, 102). Intrafraction movement of the prostate is 
variable and tends to be in the anterior-posterior and superior-inferior directions, and is due 
to physiological motions including peristalsis and pelvic floor muscle changes(103-105). IGRT 
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uses kV x-rays or cone beam CT imaging to localise the treatment target. Fiducial markers 
inserted within the prostate can act as a surrogate of prostate positioning(106, 107). On-
board imaging can be performed daily prior to each fraction to help track internal organ 
motion. By being able to determine the positioning of the intended target volume before 
each fraction, it allows precise RT delivery and reduction of the treatment volume margins 
used(4, 87, 94, 96). This is crucial as geographical miss is a significant risk factor for future 
relapse(108). Both IMRT and IGRT are now considered standard in prostate radiotherapy. 
Several studies have shown the overall survival benefit of hormone therapy + radiotherapy 
over hormone therapy alone (Table 1-6). SPCG-7 showed that if radiotherapy is given in 
addition to hormone therapy for locally advanced disease, 10 years prostate cancer specific 
mortality and overall mortality reduced significantly (23.9% vs. 11.9%, and 39.4% vs. 29.6% 
respectively)(73). PR07 included comparatively higher risk patients and confirmed that the 
addition of radiotherapy to hormone therapy significantly improved 10 year overall survival 
(55% vs. 49%) and 10 year biochemical progression-free rate (63% vs. 27%). The 
radiotherapy toxicities were modest, and G3 toxicities were uncommon(109, 110). These 
studies provide strong evidence for the use of radiotherapy with hormone therapy for men 
with locally advanced prostate cancer, even with modest radiation doses when compared to 
the modern standard used in the current era of at least 75.6 Gy(75). In addition, Mottet et 
al. showed that the addition of RT to 3 years of hormone therapy in locally advanced disease 
improved 5 year progression free survival (64.7% vs. 15.4%), but overall survival and disease-
specific survival may require longer follow-up to be assessed(111). Even for patients with 
pelvic node positive disease, the addition of radiotherapy to hormone therapy led to 
improved failure free survival (81% vs. 53%), although longer follow up is required to 
determine any improvement in overall survival(112). 
Local disease control in high-risk prostate cancer patients is associated with reduced risk of 
distant metastasis and cancer-specific mortality, and hence it is important to optimise local 
disease control(19, 92). Relapse following radical radiotherapy can be local due to 
geographic miss or intrinsic radioresistance(12, 20). Regional or metastatic relapse may 
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1.4.2 Whole prostate dose escalation RT 
Large prospective trials have consistently shown that higher doses given in standard 1.8 Gy 
to 2 Gy fractions favour improved biochemical control and disease specific survival which is 
maintained for up to 10 years follow-up, with around a 12% improvement in control for a 10 
Gy increase in dose(4)(Table 1-7). This was found whether radiotherapy was given with 
hormone therapy (MD Anderson study, Dutch trial, RT01) or without hormone therapy 
(PROG/ACR95-09, GETUG 06, RTOG 0126). Zelefsky et al. retrospectively reviewed 2,047 
patients treated by 3DCRT with doses between 66 Gy and 86.4 Gy, and found no differences 
in biochemical relapse free survival or distant metastasis free survival for low risk patients, 
but significant improvement with higher doses for intermediate and high risk patients(113). 
The evidence for whole prostate escalation radiotherapy is strongest for intermediate and 
high risk, with MD Anderson finding most benefit for those with PSA > 10 ng/ml, and GETUG 
06 for those with PSA > 15 ng/ml. Another large retrospective non-randomised study found 
that intermediate and high risk patients did derive an overall survival benefit when treated 
with 75.6 Gy to 90 Gy total doses when compared with 68.4 Gy to <75.6 Gy(114). Finally, the 
RT01 trial (which compared 64 Gy with 74 Gy) used hormone therapy in all patients, and 
confirmed benefit in biochemical control with the higher dose although overall survival was 
not significantly improved(115). 
With this improvement in biochemical control from dose escalation, toxicity also increases 
in tandem(87). These studies had used various different toxicity grading tools, but had all 
used versions of RTOG scoring which allows some comparison between them (Table 1-7). 
Acute toxicity was similar between lower and higher doses but PROG/ACR 95-09 did show 
higher acute GI toxicity with higher doses, and RT01 showed more patients had G≥2 GU and 
GI toxicity between 8 to 10 weeks, although they settled and were similar at around week 
12 and 18. 
In comparison, late toxicity was higher with higher doses, especially for GI (MD Anderson, 
Dutch study, GUTUG 06, RT01, and RTOG 0126) although two trials also showed this for 
urinary toxicity (GETUG 06 and RTOG 0126). A meta-analysis showed that dose escalation 
using 3DCRT increased significantly the risk of late G2 GU and GI toxicity(116). 
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It should be noted that many studies did not use IMRT and IGRT, which can reduce and limit 
radiation doses to organs at risk and improve conformity and homogeneity in the CTV. 
However, for organs at risk inside or close to the prostate CTV, for example urethra, anterior 
rectal wall or base of bladder, these risks cannot be reduced unless the dose is reduced. 
In summary, increasing radiation doses can improve biochemical control but the dose is 
ultimately limited by toxicity from dose to surrounding organs at risk(20). Current accepted 
clinical practice for intermediate and high risk patients usually involves a total dose of > 76 




Table 1-7 Studies on whole prostate dose escalation radiotherapy 



















GU toxicity GI toxicity 
Toxicity 
score used 








T1b - T3, N0, 
M0 
70 Gy or 78 
Gy (2 Gy per 
fraction) 
4 field box 
technique up 
to 46 Gy. For 
70 Gy arm, 
rest of dose 
delivered 
with smaller 
field sizes. For 
78 Gy arm, 
rest of dose 
delivered by 








At 8.7 years, 




70 Gy (78% 
vs. 59%; p < 
0.01) 
For 70 Gy 
and 78 Gy, 
G≤2 was 90% 
and 97% (p > 
0.4), G3 for 1 
patient per 
group, G4 
for 2 and 0 
patients 
respectively 
For 70 Gy 
and 78 Gy, 
10 year 
incidence of 
G≥2 was 8% 
and 13% (not 
sig 
different), 
G3 was 5% 
and 4% 
respectively 
For 70 Gy 
and 78 Gy, 
G≤2 was 97% 
and 100% (p 
> 0.4), G3 for 
no patients, 
G4 for 0 and 
1 patien 
respectively 
For 70 Gy 
and 78 Gy, 
10 year 
incidence of 
G≥2 was 13% 
and 26% (p = 
0.013); G3 
was 1% and 
7% 
respectively 













T1b - T4, N0, 
M0 
68 Gy or 78 






used in 30% of 
patients (6 
months or 3 
years) 
At 9 years, 78 
Gy had better 
bioochemical 
control than 
68 Gy (54% 
vs. 47%; p = 
0.03), but not 
overall 
survival (69% 
vs. 69%; p = 
0.9).  
For 68 Gy 
and 78 Gy, 
G≤2 was 40% 
and 42% 
respectively, 




(p = 0.5) 
For 68 Gy 
and 78 Gy, 7 
year 
incidence of 
G≥2 was 41% 
and 40% 
respectively 
(p = 0.6), 
G≥3 was 12% 
and 13% 
respectively 
(p = 0.6), G4 
was 1% in 
both arms 
For 68 Gy 
and 78 Gy, 
G≤2 was 41% 
and 47% 
respectively, 
and G3 was 
6% and 4% 
respectively 
(p = 0.5) 
For 68 Gy 
and 78 Gy, 7 
year 
incidence of 
G≥2 was 25% 
and 35% 
respectively 
(p = 0.04), 
G≥3 was 4% 
and 6% 
respectively 
(p = 0.3), G4 


















T1b - T2b, PSA 
≤ 15 ng/ml 
(58% were low 
risk) 
70.2 Gy or 
79.2 Gy (50.4 











to prostate to 
70.2 Gy or 








At 10 years, 




70.2 Gy (83% 
vs. 68%; p < 
0.01), but not 
overall 
survival  (78% 
vs. 83%; p = 
0.41) 
For 70.2 Gy 
and 79.2 Gy, 
G≥2 was 54% 
and 63% 
respectively, 
G≥3 was 3% 
in both arms 
(p = 0.07) 
For 70.2 Gy 
and 79.2 Gy, 
8.9 year 
incidence of 
G≥2 was 24% 
and 29% 
respectively, 
G≥3 was 2% 
in both arms 
(p = 0.79) 
For 70.2 Gy 
and 79.2 Gy, 
G≥2 was 45% 
and 64% 
respectively, 
G≥3 was 1%  
in both arms 
(p < 0.01) 
For 70.2 Gy 
and 79.2 Gy, 
8.9 year 
incidence of 
G≥2 was 13% 
and 25% 
respectively, 
G≥3 was 0% 
and 1% 
respectively 















T1b - T3a, N0, 
M0 
70 Gy or 80 









At 5 years,80 
Gy was not 
better than 
70 Gy in 
biochemical 
control (76% 








For 70 Gy 
and 80 Gy, 5 
year 
incidence of 
G≥2 was 10% 
and 17.5% 
respectively 
(p < 0.05) 
- 
For 70 Gy 
and 80 Gy, 5 
year 
incidence of 
G≥2 was 14% 
and 19.5% 
respectively 








T1b - T3a N0 
M0 (43% high 
risk) 
64 Gy or 74 







to cover flare 
(3 to 6 months 
before RT until 
end of RT) 
At 10 years, 
74 Gy was 
better than 
64 Gy in 
biochemical 
control (55% 
vs. 43%, p < 




For 64 Gy 
and 74 Gy, 
incidence of 
G≥2 was 38% 
and 39% 
respectively 
For 64 Gy 
and 74 Gy, 5 
year 
incidence of 
G≥2 was 8% 
and 11% 
respectively 
(p = 0.14) 
For 64 Gy 
and 74 Gy, 
incidence of 
G≥2 was 30% 
and 33% 
respectively 
For 64 Gy 
and 74 Gy, 5 
year 
incidence of 
G≥2 was 24% 
and 33% 
respectively 















risk (cT1b - T2b 
with Gleason 2 
- 6 and PSA ≥ 
10 and < 20, or 
Gleason 7 and 
PSA < 15)  
70.2 Gy or 

















vs. 57%, p < 





For 70.2 Gy 
and 79.2 Gy, 
10 year 
incidence of 
G≥2 was 10% 
and 15% (p < 
0.01) 
- 
For 70.2 Gy 
and 79.2 Gy, 
10 year 
incidence of 
G≥2 was 16% 








1.4.3 Hypofractionated RT 
Conventional fractionation schedules require 7 to 8 weeks of daily treatments, which can be 
logistically and financially challenging for patients, and it limits patient throughput for the 
finite health resources in the NHS, with its limited number of available linear 
accelerators(92). 
Radiobiological studies have shown that prostate cancer has a low alpha/beta ratio of 
around 1.8 Gy(129). A low alpha/beta ratio allows greater sensitivity to increasing fraction 
size(130). The alpha/beta ratio of surrounding late reacting OAR such as rectum and bladder 
are higher at around 3 to 4 Gy. Therefore hypofractionation can improve the therapeutic 
ratio(131). Currently, two broad categories of hypofractionated radiotherapy are 
recognised: moderate hypofractionation (around 2.5 Gy/# to 3.5 Gy/#) and extreme 
hypofractionation (> 5 Gy/#). 
For disease control, several randomised trials of moderately hypofractionated schedules 
have demonstrated non-inferior biochemical control compared to conventional 
fractionation of around 1.8 Gy/# to 2.0 Gy/# with a trend in favouring hypofractionation, 
including a large UK based study called CHHiP which showed that 60 Gy/20 # is non-inferior 
to 74 Gy/37 # in disease control (Table 1-8). However one trial, the MD Anderson study, did 
demonstrate a significant improvement in treatment outcome with 2.4 Gy/# (72 Gy total 
dose) over 1.8 Gy/# (75.6 Gy total dose) over 8.4 years despite being a small study with an 
increase of 0.6 Gy/# only(132, 133). 
For toxicity, there are differences between acute and late toxicity (Table 1-8). For acute 
toxicity, Pollack and NRG0415 did not find differences in urinary or bowel toxicity (although 
the former found that patients with pre-existing impaired urinary function had significantly 
worse function after hypofractionated radiotherapy), but PROFIT and HYPRO did show more 
acute GI toxicity but not more acute GU toxicity(134-137). This may have been due to the 
lack of image guidance, including the seminal vesicle in the high dose planning volume, and 
bladder dose constraints used in radiotherapy planning and delivery for HYPRO. CHHiP found 
that acute toxicity in the hypofractionated arms had faster onsets and higher peaks, and also 
returned to baseline faster. For late toxicity, MD Anderson and Arcangeli found no difference 
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in late GU toxicity (although urinary toxicity continued to increase after 4 years in the latter), 
whilst NRG 0415 and PROFIT showed more late GI toxicity with hypofractionation. It should 
be noted that Lieng found that 66 Gy in 3.3 Gy/# was associated with significantly worse GI 
toxicity that 60 Gy in 3.0 Gy/#. This shows a steep normal dose response curve, with 66 Gy/22 
# meeting their early stopping rules even though both arms had the same dose constraints. 
Although most of these studies are large multi-centre randomised controlled trials, the data 
are not yet mature enough to indicate very late effects. One single institution study, 
comparing 80 Gy/40 # and 62 Gy/20 #, found an actuarial estimate of haematuria of 9.7% 
and 24.3% respectively at 8 years (p < 0.01)(138). Therefore continued monitoring of 
patients beyond 10 years is required. 
Overall, the studies have demonstrated that contemporary radiotherapy techniques with 
IMRT and IGRT allow the safe implementation of moderate hypofractionation schedules 
which have been accepted as non-inferior to conventional fractionation at 5 years follow up, 
with increased but well-tolerated and acceptable GI toxicity profiles(92, 108). Since last year, 
60 Gy/20 # has been adopted as the standard of care for prostate radiotherapy in the UK as 
a result of the CHHiP study(87, 139, 140). 
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and 2.5 
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4.0% in both 
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was 22% in 
both groups 
(p = 0.98), 




(p = 0.33) 
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10% and 16% 
respectively (p < 
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was 0.5% and 
0.7% respectively 
(p = 0.74) 
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31% and 42% 
respectively (p < 
0.01) 
For 2.0 Gy/# 
and 3.4 















1.4.4 Dose painting RT 
The standard treatment approach to prostate radiotherapy involves the delivery of a 
homogeneous treatment dose distribution to the whole organ, in part due to the inability of 
identifying tumours on planning CT scans(20, 147). However, improved imaging modalities 
have now allowed the visualisation of intra-prostatic lesions as discussed above. 
Studies have investigated treating only the intra-prostatic lesions instead of the whole organ, 
but found that this leads in worse biochemical outcomes(4). This may be due to multiple 
factors, including geographic miss of intended targets and that the disease may be multifocal 
with microscopic disease not identified on imaging and therefore not included in treatment 
volumes. Therefore it remains crucial to maintain an adequate dose to the whole organ(92). 
Instead of dose escalating to the whole prostate which comes at the cost of increased 
toxicity, it would be rational to perform focal dose escalation to regions with high risk of 
potential recurrence whilst treating the whole prostate to an adequate dose (dose painting 
radiotherapy), thereby optimising both disease control and preserving erectile, urinary and 
rectal function. As discussed previously, prospective randomised clinical trials have shown 
that the addition of hormone therapy to RT improves overall survival, whilst whole organ 
dose escalation has not with the follow up durations so far. As the trials on combining 
hormone therapy and RT were performed with low radiotherapy doses, the survival benefit 
of hormone therapy (short and/or long course) may be reduced or lost if dose escalation is 
performed with modern techniques(75). Therefore it may be possible to reduce the duration 
hormone therapy if these new techniques are used. 
Determining a clinically relevant, high risk region within the prostate that would benefit from 
dose intensification is a prerequisite for dose painting radiotherapy(20). Macroscopic 
disease is more treatment resistant than microscopic disease, and disease recurrence has 
been shown to usually occur at the site of the dominant lesions at staging(4, 87, 148). 
Therefore these lesions often drive the natural progression of the cancer, and it would be 
reasonable to use macroscopic disease (referred to as dominant intra-prostatic lesions 
(DILs)) with a margin to create boost volumes(20). 
55 
 
Both functional MRI and PET can provide complimentary information(4, 14). Combined 
boost volumes from different imaging modalities will be larger with a higher toxicity risk, but 
may include more of the primary tumour volumes and hence may be more effective than 
using a single imaging modality alone. These imaging modalities are fused to the planning CT 
scan. Multi-modality image registration involves a geometric transformation to align 
landmarks between the corresponding scans. Implanted fiducial markers within the prostate 
can be used as points of reference given that the in vivo configuration of prostate in relation 
to surrounding tissues will be altered by differing bladder and rectal filling(20). Registration 
can be performed manually with the clinician using their visual judgement, or automatically 
by rigid (allowing only linear transformations e.g. translation and rotation) or deformable 
(allowing warping to potentially achieve better matching) registration(11). Both manual and 
automatic registrations of the prostate between CT and MRI are comparable(149). 
Deformable registration may not be available with some planning softwares and the 
expertise for it may not be present at some treatment centres, and so rigid registration is 
often used(20). 
Avoiding geometric miss is especially important for prostate dose painting radiotherapy as 
the target boost volumes are relatively small, and increased toxicity may occur if organs at 
risk migrate into the dose escalation region. For example, if boost volumes are located at the 
peripheral zone of the prostate, the rectum may move within the boost region(20). Both 
delineating and radiotherapy planning are based on a scan performed at a specific time 
point, with which a course of treatment is delivered over several weeks. Hence the actual 
treatment received by a patient may not reflect the dose distribution planned, and 
accounting for target movement is crucial(150). Therefore image guidance is a prerequisite 
to safely achieve dose painting(151). 
Boost volumes can be defined using either the DILs or by the region of the prostate. The 
former involves identifying the clinically significant lesions. This can be based on size, 
features on imaging such as intensity of tracer uptake on PET, and any other information 
such as Gleason score on template biopsies. This delineating is a subjective process based 
on clinician judgement. For instance, some would argue that lesions of < 0.5 mls will not 
require dose escalation as they would be treated adequately by the standard dose, and that 
larger lesions are more likely to determine future clinical progression(11). The other strategy 
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of boosting a whole region of the prostate (e.g. the middle third of the right side of the 
prostate) has the benefit of treating multiple tumour foci, but would result in dose escalating 
more extensive volumes of the prostate (11). 
The higher biologically effective radiation dose for dose painting can be produced by 
delivering a higher total dose or higher dose per fraction(20). The former can be achieved by 
sequential boosting, whereby standard radiation is delivered to the whole organ in the initial 
phase, followed by additional focused treatment to the boost volume. This is suitable for 
tumour sites where treatment should ideally be instigated without delay, and it allows the 
use of different radiotherapy methods including electrons to be combined to produce the 
desired dose distributions(20). However, tissue response to the initial phase complicates 
subsequent registration for the following boost phase which often uses pre-treatment data 
for planning. Also, the sequential boost strategy often increases doses to the PTV outside 
the boost volume as there is spill over from the phase II into the phase I volume and can 
increase normal tissue doses. In comparison, dose painting by using higher doses per fraction 
can be delivered by simultaneous integrated boost (SIB), whereby IMRT (static or rotational) 
can be used to plan a heterogeneous dose distribution with a concomitant boost, all in a 
single phase. In comparison with sequential boosting, this allows the need for one 
radiotherapy plan only and should therefore improve conformality(20). 
Dose painting have already been used for prostate radiotherapy and other sites(20, 152). 
For the former, previous dosimetric studies have shown that it is feasible to deliver a boost 
dose to MRI defined intra-prostatic lesions without compromising the dose to the whole 
prostate or the dose constraints to surrounding organs at risk(153-156). For treatment 
delivery, different techniques have been combined including EBRT, brachytherapy and 
stereotactic radiosurgery. 
Studies which have only used EBRT for prostate dose painting radiotherapy are shown in the 
Table 1-9. Intra-prostatic lesions have been identified by various methods: MRI, SPECT and 
PET. In the non-randomised studies where dose painting was performed if intra-prostatic 
lesions were identified, the proportion of patients who received dose painting varied from 
51% to 69%. Of note, Wong et al. (which was a single cohort study) reported that 28% of 
patients did not have uptake on ProstaScint, and Schild found that 21% of patients did not 
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have an intra-prostatic lesion on MRI, whilst Pinkawa found that ≥ 3 lesions were found in 
13% of patients(157-159). As expected, IMRT was used to deliver the boost doses for all the 
studies, and daily IGRT methods used included ultrasound, CBCT, and fiducial markers 
(ultrasound based studies predated the use of fiducial markers). The margin added to the 
intra-prostatic lesions varied from no margin (e.g. Sundahl) to 15 mm (Ippolito)(158, 160). 
All the studies used SIB except Miralbell which used sequential phase II boost of up to 16 Gy 
in 2# (this study was the only one that delivered pelvic radiotherapy (50.4 Gy/28 #) also, to 
56% of patients)(101). The EQD2 to prostate varied from 64 Gy to 81 Gy, and EQD2 to boost 
varied from 80 Gy to 114 Gy. 
Despite these boost levels, the toxicity levels reported were clinically safe and FLAME 
reported no significant difference in toxicity up to 2 years follow up between patients 
receiving standard treatment and those receiving dose painting. For late urinary toxicity, 
patients with prior TURP were more likely to develop late urinary incontinence (Sundahl) 
and toxicity was related with prostatic urethral dose (Ippolito). Late rectal toxicity was 
related to higher rectal Dmean and V30 mean values (Ippolito). 
Most of these dose painting prostate radiotherapy studies have used conventional dose 
fractionations. Only one study has investigated this technique using the current UK standard 
moderately hypofractionated dose fractionation of 60 Gy/20 #/4 weeks(161). This small pilot 
study of 28 patients with intermediate and high risk prostate cancer was performed at the 
Clatterbridge Cancer Centre NHS Foundation Trust, and used mpMRI to identify DILs to 
which a boost dose of up to 68 Gy were delivered. Most of the patients achieved 68 Gy boost 
(25 out of 28 patients), and the rest achieved 67 Gy only due to proximity of DIL to urethra 
and rectum. With follow up of at least 32 months, no patients had grade 3 urinary or bowel 
toxicity, and only 3 patients had disease relapse. As a result of the low toxicity levels in this 
pilot study, the phase II single arm BIOPROP20 clinical trial was established. 
Other treatment modalities specifically targeting the DILs without the sole use of 
conventional external beam ionising radiation are also being investigated. Brachytherapy 
involves either the permanent implantation (low dose rate, LDR) or temporary placement 
(high dose rate, HDR) of radiation sources directly into the target, and can be performed 
alone or in combination with external beam radiotherapy for focal dose escalation. 
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Stereotactic ablative body radiation (SABR) therapy involves the delivery of a high ablative 
dose to the target in a few fractions (often < 5) whilst avoiding surrounding OARs via steep 
dose gradients by using precise targeting, effective immobilisation, and tumour motion 
management. For brachytherapy, the mean EQD2 boost dose (if α/β ratio for prostate is 1.5 
Gy) that has been delivered in clinical trials is 178 Gy (range 150 to 217 Gy, with average 
differential dose when compared to the non-boosted prostate of 62 Gy) by LDR, and 106 Gy 
(range 90 to 151 Gy, with average differential dose of 32Gy) by HDR(162). For SABR, the 
mean EQD2 boost dose has been 136 Gy (range 90 to 164 Gy, with average differential dose 
of 45 Gy). Available biochemical disease-free survival (bDFS) for LDR was 85% to 98% at 5 
years, for HDR was 71% to 100% at 5 years, and for SABR was 96% to 100% at 2 years. In 
terms of side effects, the median G≥3 acute and late GU toxicity were 0% and 2% for LDR, 
3% and 5% for HDR, and 6% and 6% for SABR respectively. The median G≥3 acute and late 
GI toxicity were 0% and 6% for LDR, 0% and 4% for HDR, and 2% and 10% for SABR 
respectively. Overall, these techniques allowed increased differential doses between the 
boosted and non-boosted prostate when compared to using EBRT alone (differential dose of 
18Gy in BIOPROP20). 
Techniques specifically targeting the DILs without the use of ionising radiation include 
cryotherapy and high-intensity focused ultrasound (HIFU). Case series have been reported 
for both technologies. These treat the tumour volume with a 6-8 mm margin, but not the 
whole prostate. Cryotherapy is an invasive procedure often with the patient under general 
anaesthetic where consecutive freezing and thawing of the target leads to cytolysis. A UK-
based series of 122 patients with intermediate (71%) and high (29%) risk disease had a 3 
years failure free survival of 91%, with 0% patients having urinary incontinence and 16% 
having erectile dysfunction(163). HIFU involves delivering focused ultrasound waves to 
create irreversible coagulation necrosis and tumour lysis in a target by thermal effect. A UK-
based series of 625 patients (84% had either intermediate or high risk disease) had a 5 years 
failure free survival of 88%, with 2% having urinary incontinence(164). The maximal length 
of HIFU systems currently available is up to 67 mm, and so this technique is limited in large 
prostates and anterior DILs. 
Other techniques investigated include focal laser ablation (FLA), photodynamic therapy 
(PDT), and irreversible electroporation (IRE)(165). FLA uses high energy laser light delivered 
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by fibres inserted transperineally for thermal ablation. Post treatment positive biopsies 
ranged from 4 to 64% with up to 12 months follow up(166). PDT uses the interaction 
between light from intraprostatic laser fibers and either an oral or intravenous 
photosensitive agent, which results in production of reactive oxygen species causing 
thrombosis within the target. Post treatment positive biopsies ranged from 26 to 51% with 
up to 24 months follow up(166). IRE involves generating an electric field to increase cell 
membrane permeability and resultant apoptosis. Post treatment positive biopsies ranged 
from 3 to 33% with up to 12 months follow up(166). FLA and IRE were associated with <1% 
urinary incontinence, whilst PDT was associated with <5% urinary incontinence. Overall, 
these techniques have been used in small studies and require specialist equipment which 
are not widely available currently. 
In summary, the objective of dose painting radiotherapy is to improve therapeutic ratio by 
achieving optimal local control with minimal effect on toxicity(87). Focal dose escalation, 
biologically or in conventional fractionation, requires accurate treatment delivery. It is 
suggested that BED of up to 200 Gy (at α/β of 1.5, corresponding to around 86Gy in 2 Gy/#) 
will improve disease control, with limited further benefit beyond that dose(167). 
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Table 1-9 Studies on dose painting radiotherapy to prostate using EBRT 
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1.4.5 Pelvic lymph node radiotherapy 
For clinically node negative disease, patients with high risk features may have micro-
metastases in pelvic lymph nodes, and therefore the addition of pelvic nodal radiotherapy 
may lead to survival advantages compared to prostate radiotherapy alone(75). However, no 
prospective randomised trial have so far demonstrated overall survival benefit from 
prophylactic pelvic lymph node irradiation with conventional dose fractionations (46 to 50 
Gy)(173). RTOG 94-13 and GETUG-01 did not show a difference in progression free survival 
between all patients receiving whole pelvis radiotherapy and all those receiving prostate 
only radiotherapy (Table 1-10)(174). However these studies were performed before the 
modern era of IMRT and dose escalation radiotherapy, and hence the nodal dose of 46 Gy 
in 23 # used at the time may have been suboptimal. Also, GETUG-01 used a lower superior 
border of the pelvic field and most patients had <15% risk of lymph node involvement (Roach 
formula). More recently, PIVOTAL showed that the addition of high dose pelvic radiotherapy 
(60 Gy in 37 #) to prostate radiotherapy using modern IMRT +/- IGRT is well tolerated, but 
its effect on disease control is not yet established(175). Mature data from PIVOTAL and the 
ongoing RTOG 09-24 trials will determine the benefits of whole pelvic radiotherapy with 
conventional dose fractionations using modern technology. Another notable trial (RTOG 
0924) is a large randomised phase III trial with a recruitment aim of 2580 patients with high 
risk disease and aimed to treat pelvic nodes to 45 Gy/ 25 #, but there are no published results 
as yet(176). Current guidelines generally suggest that high risk clinically node negative 
patients should be considered on an individual basis for prostate and pelvic lymph node 
radiotherapy(75). 
For clinically node positive disease, there is a lack of prospective randomised control trials 
to determine the optimal treatment regime. A large retrospective study using the National 
Cancer Database (2003 – 2011) found that local treatment (radical prostatectomy or 
radiotherapy) may be associated with overall mortality-free survival when compared to 
hormone therapy alone(177). Another large retrospective study using the SEER Database 
(1995 – 2005) found that local treatment (radiotherapy +/- prostatectomy) improved overall 
survival and prostate cancer specific survival compared to no local treatment(178). Overall, 
definitive local radiotherapy with conventional dose fractionation for clinically node positive 
disease is associated with 5 year overall survival of around 70%(179). In terms of pelvic 
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radiotherapy with conventional dose fractionation for clinically node positive disease, 
patients who were randomised into the control arm of the STAMPEDE trial were offered 
optional radiotherapy including to the pelvis. These 71 patients (82% received radiotherapy 
to both prostate and pelvis; 89% received conventional dose fractionation) had 5 year overall 
survival of 71%(112). 
Hypofractionated dose fractionations have been used in several studies for pelvic nodal 
radiotherapy (Table 1-11). One randomised trial for node negative patients, which compared 
76Gy/38# to prostate and 46Gy/23# to LN, with 63Gy/20# to prostate and 44Gy/20# to LN, 
found that GI and GU toxicity both occurred and settled faster with the hypofractionated 
arm(180). Single cohort studies for node positive patients have shown that hypofractionated 
IMRT is feasible with temporarily increased toxicity but is generally well tolerated(181, 182). 
A concern with simultaneous prostate and pelvic radiotherapy with a hypofractionated 
schedule is accurate delivery to both the prostate and the pelvic lymph nodes when both 
may not move in tandem, providing a technical challenge. Current clinical practice for 
concurrent prostate and pelvic radiotherapy with standard fractionation usually involves 
matching bony anatomy between planning CT and on board cone beam CT without fiducial 
markers and using wider margins to PTV to account for set up errors. 
Overall there are no randomised trials in either the node negative or node positive settings 
which have shown overall survival benefit with the addition of pelvic nodal radiotherapy to 
prostate radiotherapy. As a result, although it is technically feasible, the selection criteria 
remain undefined. If offered to the patient, long term hormone therapy is preferable due to 
poor outcomes(84, 183). 
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 Toxicity and Quality of Life scores 
As well as efficacy, important endpoints when considering novel radiotherapy techniques 
are both acute and late toxicity, especially as prognosis is generally good after radical 
prostate radiotherapy and so survivorship issues are paramount(186). Commonly used 
clinician assessed toxicity scores include Common Terminology Criteria for Adverse Events 
(CTCAE) and Radiation Therapy Oncology Group (RTOG – which uses different scoring 
systems for acute and late toxicity), and commonly used patient reported outcome scores 
include Expanded Prostate Cancer Index Composite (EPIC) and International Prostate 
Symptom Score (IPSS) (75, 96, 187). Both clinician assessed scores and patient reported 
outcomes are complementary and allow a holistic assessment of the treatment. 
Clinician assessed scores consist of standardised definitions that describe the severity of 
toxicities and a grade is assigned by the clinician according to symptoms reported by the 
patient. RTOG has been the histological gold standard for acute toxicity, but it tends to 
combine several symptoms into one overall score and so may lead to loss of information. 
Many of the late toxicity items are very rare or not seen any more at all with the current 
radiotherapy technology. A number of different modifications have been devised over the 
years to improve the capture of different side effects. It is however simple to use and most 
prostate radiotherapy trials still report the RTOG toxicity score for comparison with other 
studies. In comparison, CTCAE is generally more descriptive and comprehensive. The 
proportion of radiation studies utilising CTCAE has been increasing and it is becoming the 
commonly used standard(188). CTCAE and RTOG are similar but not equivalent. For instance, 
in terms of the actual scores themselves, rectal bleeding requiring transfusion is grade 3 by 
CTCAE v4.0 but grade 4 by RTOG, and in terms of clinical use of the scores in prostate cancer 
patients treated with HDR brachytherapy alone, CTCAE v3.0 identified more G1-2 GU 
adverse reactions than RTOG(189). EPIC is an expansion of the University of California – Los 
Angeles Prostate Cancer Index (UCLA-PCI) validated health-related quality of life 
questionnaire and is a patient reported outcome measure that categorises by urinary 
function, bowel habits, sexual function, and hormone function. IPSS is a short efficient 
questionnaire to screen and track urinary symptoms, although a weakness of it is the lack of 
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haematuria scoring(190). Overall, clinician assessed scores can predict significant clinical 
events, whilst patient reported outcomes can better reflect the daily health status of the 
patient(191). 
It is recognised that clinician assessed scoring frequently reports symptoms as less severe 
than from the patient’s perspective and so underestimate the effects on the patient’s quality 
of life, thereby limiting their sensitivity in detecting subtle changes(192). For instance, EPIC 
was more sensitive to changes in acute bowel toxicity during a course of prostate 3DCRT 
treatment than RTOG(193). With technological advances in radiotherapy delivery, it is 
important that these toxicity assessment tools are able to detect subtle but clinically 
meaningful changes in toxicity when assessing their clinical impact. Furthermore, it should 
be noted that a statistically significant change in toxicity on a clinician score may not be 
clinically relevant from the patient’s perspective, and vice versa(75). 
Assessing pre-treatment baseline symptoms as well as acute toxicities is critical as they can 
both influence late sequaelae(171). For example, spontaneous erections prior to treatment 
can predict subsequent maintenance of erectile function after treatment, a lack of acute 
RTOG GI adverse reaction could predict lack of late adverse reaction such as radiation 
proctitis, and those that developed acute G≥2 CTCAE GI and GU symptoms from 3DCRT and 
IMRT had a 7 and 3.5 fold increased risk of late GI and GU toxicities respectively(96, 189, 
194, 195). Therefore, collecting pre-treatment symptomatic data as well as acute toxicity 
data is of importance. 
Uneven reporting standards between studies, due to use of different toxicity scores at 
different time points in relation to radiotherapy, can make comparing therapy effects 
difficult(96, 160). Therefore, to assess the toxicity of hypofractionated dose painting 
radiotherapy, it would be prudent to use well established toxicity scoring tools that have 
already been used by preceding studies to facilitate consistency and comparison. 
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2 Dynamic 18F choline tracer uptake on PET/CT in prostate 
cancer and the effects of bicalutamide on it 
 Introduction 
For prostate dose painting radiotherapy, an imaging modality that can be used to identify 
boost volumes is PET/CT. This can be performed at staging (before any treatment has 
commenced) or at planning (during hormone therapy). The former ensures that imaging is 
not affected by hormone therapy, whilst the latter would minimise changes to anatomy that 
may result in the 2 - 3 months period between imaging and planning, such as prostate 
shrinkage due to hormone therapy. The latter would have the added advantage of 
potentially using the PET/CT as the planning CT, so as to minimise patient radiation exposure 
and improve convenience. Therefore the effect of hormone therapy on PET tracer uptake is 
of interest to determine the optimal timing of PET imaging. This would also be informative 
for other tracers such as PSMA which is now increasingly used to identify sites of disease 
recurrence following PSA relapse, and may be performed before or after initiation of 
hormone therapy. 
PET imaging can provide static imaging (where activity at a certain time point is analysed and 
represented in a fixed image) or dynamic imaging (where sinogram data is collected 
continuously which can be binned into specific static time intervals, capturing the change in 
activity for individual voxels over time in the form of time activity curves (TAC)). 
For dynamic imaging in prostate adenocarcinoma with choline PET, only a few studies have 
been performed. 11C choline was used in only one study of 14 patients of whom only 3 
patients were on hormone therapy at the time of imaging, and visual evaluation found that 
hormone therapy resulted in low prostatic tracer accumulation(196). 18F choline was used in 
four studies, but none of the patients were on hormone therapy at the time of imaging(197-
200). Therefore the effects of hormone therapy on 18F choline dynamic uptake is not known. 
For static imaging, DIL delineation with choline PET can be performed manually (i.e. visually) 
or automatically (i.e. using an SUV threshold). With the latter, the optimal threshold for 11C 
choline PET/CT was been shown to be 60% of prostate SUVmax, but there has been no studies 
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to determine the optimal threshold for 18F choline PET/CT although various thresholds have 
been used(201). Pinkawa et al. defined the DIL by a tumour-to-background uptake value 
ratio of > 2(171). However the disadvantage of this is their definition of background (an area 
of around 1 cm2 within the prostate with the lowest activity on visual assessment, and the 
SUVmax in this area was used as the background uptake value) is subjective and so is not 
reliably reproducible. 
At the Clatterbridge Cancer Centre, an institutionally approved pilot study on prostate dose 
painting radiotherapy was conducted before the BIOPROP20 study (phase II single cohort 
study on moderately hypofractionated prostate dose painting radiotherapy) was initiated. 
For this, consented patients received 18F choline PET/CT imaging during which a dynamic 
imaging sequence was performed. Initially, patients had imaging whilst on bicalutamide. 
However as the tracer uptake was felt to be low on visual assessment, subsequent patients 
had imaging before starting bicalutamide. For this chapter, I have retrospectively analysed 
the dynamic scans available from the pilot study and those that were available from the 
ongoing BIOPROP20 trial at the time of writing this chapter. 
 Aims 
To describe the effect of bicalutamide on the differences in the TAC between tumour and 
benign prostatic tissue for 18F choline PET/CT. 
 Method 
2.3.1 Patients selection (inclusion and exclusion criteria) 
Newly diagnosed patients were considered if eligibility criteria were fulfilled: 
2.3.1.1 Inclusion criteria 
• Histologically confirmed prostate adenocarcinoma 
• NCCN intermediate/high risk disease/locally advanced (2010 guidelines – 
Appendix 8.1) and estimated risk of pelvic lymph node involvement of 15 – 40% 
(Roach formula: ((Gleason score – 6) x 10) + 2/3 PSA) 
72 
 
• MRI staging T2a – T4, N0, M0 
• 18 – 80 years of age at registration 
• WHO PS 0 or 1 
• Fully informed written consent 
2.3.1.2 Exclusion criteria 
• Previous prostate or pelvic radiotherapy 
• Previous hormone therapy or radical prostatectomy 
• Total hip replacement 
• Clinically significant inflammatory bowel disease 
• Contraindications to MRI imaging 
2.3.2 PET/CT 
Patients had three fiducial markers inserted into the prostate at least 2 weeks before PET/CT 
imaging. Initially, patients had already commenced bicalutamide 150mg OD before imaging. 
However subsequent patients were not commenced on bicalutamide until after imaging. 
Patients were fasted for at least four hours prior to imaging and asked to drink 500 ml of 
water before an intravenous injection of 370 MBq of 18F choline (fluoroethylcholine). Starting 
simultaneously with tracer injection, a GE Discovery 690 PET/CT scanner (GE Medical 
Systems, Milwaukee, Wisconsin) was used to acquire continuous list-mode time of flight PET 
data using a single bed position over the pelvis. List-mode collection involved recording each 
photon pair detection event with a time stamp so that subsequent time-binning of the image 
data can be performed. This was performed for 30 minutes. The CT based attenuation 
correction for the PET component is 3.75 mm and the standard CT reconstruction is 2.5 mm. 
Retrospective reconstruction was performed with data binned into 40 individual time 
frames, consisting of 12 x 10 second frames, and 28 x 1 minute frames. SUV was normalised 
to body weight. 
A static PET/CT scan was also performed at 90 minutes after injection, consisting of a 10 




The prostatic volume (whole prostate and any extraprostatic extension) was manually 
delineated by a board-certified nuclear medicine consultant of over 20 years experience 
(Professor S. Vinjamuri (SV) of The Royal Liverpool University Hospital). The tumour volume 
was defined on the 90 minutes static imaging by two methods: threshold and visual 
methods. The threshold method (SUV60%) was performed by identifying the SUVmax of the 
prostatic volume, and the Hermes Hybrid3D software (Hermes Medical Solutions, 
Stockholm, Sweden) was used to automatically delineate a region within this prostatic 
volume which was ≥60% of the SUVmax. The visual method was performed by a nuclear 
medicine consultant (SV) who manually delineated on the PET/CT without access to any 
other information including histology or MRI. 
In order to transfer the tumour volumes generated from the 90 minutes static imaging to 
the dynamic imaging, the CT sequences of both scans were rigidly co-registered by using the 
three fiducial markers and these coordinates were used. 
2.3.4 Analysis 
For the tumour and benign prostatic tissues, the median SUV value within each time bin was 
calculated, and data were collected to evaluate the effect of bicalutamide on: 
1) Time to peak 90% (TT90%P) SUV (from time of tracer injection to the time where 90% of 
maximal SUV uptake is reached) of tumour and of benign prostatic tissue; 
2) The SUVmax of tumour and of benign prostatic tissue; 
3) Difference in AUC between tumour and benign prostatic tissue. 
The data for tumour and for benign prostatic tissue are presented with median and range 
values. The 95% confidence interval (CI) for the median values are also presented (as the 




Dynamic PET/CT imaging was available for 40 patients who had imaging without 
bicalutamide, and 10 patients who had imaging with bicalutamide (Table 2-1). With the 
threshold method, all 50 patients had identifiable tumour volumes. With the visual method, 
all 40 patients who had imaging without bicalutamide had identifiable tumour volumes, but 
only 7 out of the 10 patients who had imaging during bicalutamide had identifiable tumour 
volumes. As a proportion of the whole prostatic volume, the tumour volume ranged from 
1.6 % to 41.7 % (Table 2-2). 
On visual evaluation, the initial tracer uptake in the tumour and benign prostatic tissues were 
rapid within the first 5 minutes (Figure 2-1). Thereafter the TACs either plateaued or showed 
gradual increase in activity with no apparent differences in pattern between tumour and 
benign prostatic tissue (Figure 2-2 and 2-3). However the range of SUV values appear larger 




Table 2-1 Patient demographics 






No. of patients 10 40 
Age (years)* 62 (56 – 76) 68 (56 – 78) 
PSA (ng/ml)* 17.3 (10.9 – 59.1) 10.0 (4.4 – 39.4) 
Bicalutamide duration before PET/CT 
(days)* 
82 (42 – 193) - 
High risk 9 28 
Gleason score 
6 0 1 
7 5 29 
8, 9 5 10 
TNM staging 
T2 3 15 
T3 7 25 




Table 2-2 Tumour volume as a percentage of the whole prostatic volume 
 
 With bicalutamide Without bicalutamide 
Median Range Median Range 
Threshold 
method 
DIL volume (ml) 6.5 1.7 – 11.1 3.7 0.9 – 16.8 
Prostate volume (ml) 30.4 20.2 – 55.0 33.7 14.7 – 95.0 
DIL/ prostate (%) 14.2 6.6 – 32.7 9.9 2.3 – 41.7 
Visual 
method 
DIL volume (ml) 2.5 1.0 – 14.3 2.2 0.6 – 10.6 
Prostate volume (ml) 38.7 25.1 – 61.1 37.9 19.2 – 87.6 
DIL/prostate (%) 6.1 2.0 – 26.9 5.8 1.6 – 17.5 




































Figure 2-2 Example of TACs for a patient who had imaging without bicalutamide, with tumour identified by the 



































Figure 2-3 Example of TACs for a patient who had imaging with bicalutamide, with tumour identified by the threshold 





































For the group of patients who had imaging without bicalutamide, the median TT90%P SUV 
within the tumour as identified by the threshold method was 8.0 minutes, whilst that of the 
benign tissue was 9.0 minutes (Table 2-3). However there is generally a significant variation 
of TT90%P from patient to patient (for instance, TT90%P within the tumour ranged from 0.7 
minutes to 27.0 minutes). The TT90%P within the tumour occurred before that of the benign 
tissue in 18 patients, at the same time in 4 patients, and after in 18 patients. On an individual 
patient by patient basis, there was no significant difference in TT90%P between tumour and 
benign prostatic tissue (although this ranged from -23.0 to 13.0 minutes). 
For the group of patients who had imaging with bicalutamide, the median TT90%P SUV 
within the tumour as identified by the threshold method was 2.9 minutes, whilst that of the 
benign tissue was 1.9 minutes (Table 2-3). Again, there is generally a significant variation of 
TTP from patient to patient (for instance, TT90%P within the tumour ranged from 0.8 
minutes to 23.0 minutes). The TT90%P within the tumour occurred before that of the benign 
tissue in 3 patients, at the same time in 4 patients, and after in 3 patients. On an individual 
patient by patient basis, there was again no significant difference in TT90%P between 
tumour and benign prostatic tissue. 
Therefore, whether tumour is identified by the threshold or visual method, the difference in 
TT90%P of tumour and of benign tissue was not significant, whether PET/CT was performed 
with or without bicalutamide (Table 2-3). 
Also there is a trend for TT90%P without bicalutamide to be longer than with bicalutamide, 
although was no statistical significance (using independent samples Mann Whitney U test: 
with the threshold method, p value for tumour and benign were 0.22 and 0.51 respectively; 
with the visual method, p value for tumour and benign were 0.35 and 0.17 respectively). 
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Table 2-3 Time to 90% peak (TT90%P) in minutes 
*statistical comparison between tumour and benign using Wilcoxon signed rank test 
 
  Tumour Benign 
Difference in 
TT90%P between 
tumour and benign 






























































For the group of patients who had imaging without bicalutamide, the SUVmax within the 
tumour as identified by the threshold method was 5.3, whilst that of the benign tissue was 
2.9 (Table 2-4). On an individual patient by patient basis, the difference in SUVmax between 
tumour and benign tissue was statistically significant (p < 0.01). For the group of patients 
who had imaging with bicalutamide, the SUVmax within the tumour as identified by the 
threshold method was 3.4, whilst that of the benign tissue was 2.4. Again, for the individual 
patients, the difference in SUVmax between tumour and benign tissue was statistically 
significant (p = 0.01). This was also found if the tumour is identified by the visual method. 
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Therefore, whether tumour is identified by the threshold or visual method, the SUVmax of 
tumour is significantly higher than that of the benign tissue, whether PET/CT was performed 
with or without bicalutamide (Table 2-4). 
Table 2-4 SUVmax 
*statistical comparison between tumour and benign using Wilcoxon signed rank test 
 
  Tumour Benign 
Statistical 
comparison* 





3.4 3.2 to 6.2 2.4 1.9 to 3.5 0.01 
Without 
bicalutamide 





3.9 3.2 to 8.5 2.6 2.0 to 3.3 0.03 
Without 
bicalutamide 
5.6 5.0 to 6.1 3.1 2.8 to 3.2 <0.01 
       
 
 
2.4.3 Difference in AUC of the TAC between tumour and benign tissue 
When imaging was performed without bicalutamide, the AUC of the tumour as identified by 
the threshold method was larger than that of the benign tissue by a median of 1.7 times 
(range of 0.8 to 3.3) (Table 2-5). When imaging was performed with bicalutamide, the AUC 
of the tumour was larger than that of the benign tissue by a median of 1.4 times (range 1.1 
to 2.8). However this difference in AUC between tumour and benign tissue was not 
significantly different whether imaging was performed without or with bicalutamide (p = 
0.10). This was also found if the tumour was identified by the visual method. 
Therefore, whether tumour is identified by the threshold or visual method, bicalutamide 
does not significantly affect the difference in AUC between tumour and benign tissue. 
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Table 2-5 Relative difference in AUC between tumour and benign tissue 
*statistical comparison between without bicalutamide and with bicalutamide using independent 


























1.7 1.6 to 1.9 




Semi-quantitative analyses of our results show that whether using the SUV60% threshold 
method or the visual method to differentiate between malignant and benign prostatic tissue, 
there is a trend (although not statistically significant) for SUV in both malignant and benign 
prostatic tissue to peak slower when scanned without bicalutamide than when scanned with 
bicalutamide. Also the SUVmax and bicalutamide are significantly higher in tumour than in 
benign tissue, and this is not affected by bicalutamide. For these analyses of 30 minutes 
dynamic imaging, static imaging performed at 90 minutes were used as the standard with 
which to define the tumour, and around a third of patients who were imaged with 
bicalutamide had no visually identifiable tumour and therefore analysis using the visual 
method was not possible for these patients. 
The TACs generated in our study support the observations within the published literature. 
Our malignant lesions had generally rapid 18F choline uptake within the first 5 minutes then 
subsequently plateaued or continued to rise slowly. This has been described for both 11C 
choline(196) and 18F choline(197, 199). Of note, one of these studies which performed kinetic 
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studies using compartmental modelling for 18F choline had used a dynamic scan over 60 
minutes, and it found that reliable estimates of all parameters could be achieved with a 30 
minutes dynamic scan instead, thereby suggesting that our dynamic imaging protocol is 
sufficient to obtain data from(197). 
In the published literature, the only study that I am aware of which assessed dynamic choline 
PET imaging in patients during hormone therapy was by Sutinen et al., which used 11C choline 
and showed that the two patients on hormonal treatment with goserelin had the lowest 
tracer accumulation of all the studied patients, with SUV of 1.8 and 2.8(196). There was 
another patient who had orchiectomy 7 years prior to PET imaging, but his tracer uptake 
profile was not specifically described. Although our study had used 18F choline instead, it also 
showed that tumour SUV without hormone therapy is generally higher than tumour SUV 
with hormone therapy, but that the difference in SUV between tumour and benign prostatic 
tissue is statistically significant whether without or with hormone therapy. Also of note, our 
study showed that PET scanning without hormone therapy can result in a more prolonged 
and increased tracer uptake over time, whereas hormone therapy can result in a shortened 
and lower tracer uptake. Overall, this suggests that dynamic PET scanning without hormone 
therapy will allow tumour to be more easily identifiable by visual assessment than if 
performed with hormone therapy, but that hormone therapy should not affect the ability to 
differentiate between tumour and benign prostate tissue. Therefore if dynamic PET imaging 
is to be used for the purposes of identifying DILs for dose painting radiotherapy delineation, 
they should be performed without hormone therapy. 
The effect of bicalutamide on 18F choline tracer uptake may be due to modulation of 
signalling pathways. Prostate cancer cells have been shown to have an increased uptake of 
choline due to increased cell proliferation and upregulation of choline kinase. Bicalutamide 
is a pure anti-androgen which blocks androgen receptors, downregulating the expression of 
several genes including those involved in lipid metabolism and regulating the Ras signalling 
pathway, leading to reduced choline transporter and choline kinase activity as well as 
inhibiting of angiogenesis and proliferation of cancer cells(202). Bicalutamide has previously 
been found to inhibit prostate 11C choline uptake, and it is likely to have a similar effect on 
18F choline(203, 204). 
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There are limitations to our methodology. The reference standard comparator was not 
histology, but instead was the static PET imaging at 90 minutes after tracer injection. 
Therefore this requires an assumption that the 90 minutes scan can accurately identify 
malignant DILs without histological confirmation. Furthermore, the SUV60% threshold 
method used for the 90 minutes scan was derived from studies using 11C choline, and so 
there are inherent uncertainties about whether this threshold method is as accurate for 18F 
choline. Our methodology involved rigid co-registration of the CT component of the PET/CT 
scans by using three fiducial markers, in order to delineate the region of the prostate on the 
dynamic scan which was identified as malignant on the 90 minutes scan. The rigid co-
registration process between the CT components was straight forward, but there are 
inherent uncertainties between the registration of the PET and CT components. It has been 
shown that, despite a patient lying still on the imaging bed, prostate positioning can increase 
with elapsed time from physiological motions (i.e. rectal activity and bladder filling) and from 
pelvic muscular contractions, especially as the dynamic PET and static PET data were 
acquired over 30 minutes and 10 minutes respectively, whilst the associated CT imaging for 
both were taken in a significantly shorter period of time(205). This may explain the 
anomalies in Figure 2-1B, where one patient has a comparatively higher SUV than the other 
patients, and another patient has a rise in SUV after around 28 minutes. The former patient 
may have had a shift between the PET and CT components of either dynamic or static scans, 
resulting in mis-registration of the PET despite good registration between the CT scans. This 
may have led to part of the tumour migrating into the region which has been designated 
benign tissue, thereby resulting in a TAC that actually represents tumour. The latter patient 
may have also had a similar shift, resulting in the bladder or urethra migrating into the region 
which has been designated benign tissue, and so explain the delayed uptake on the TAC. 
Another limitation is that our TT90%P methodology has not been used in other studies, and 
hence it is difficult to compare our results. Also we had not performed kinetic modelling nor 
quantitative analysis. However we had performed semi-quantitative analysis with SUV, and 





Dynamic PET scanning without bicalutamide will allow tumour to be more easily identifiable 
by visual assessment than if performed with bicalutamide, but bicalutamide should not 
affect the ability to differentiate between tumour and benign prostate tissue. Therefore if 
dynamic PET imaging is to be used for the purposes of identifying DILs for dose painting 
radiotherapy delineation, they should be performed without bicalutamide.  
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3 Effect of bicalutamide on prostate dose painting 




Prostate dose painting radiotherapy requires the delineation of DILs within the target 
volumes to which an escalated dose can be delivered. mpMRI is the standard method used 
for identifying intra-prostatic lesions due to the superior soft tissue definition it affords. An 
alternative imaging modality which can be used is PET/CT with various tracers including 
radiolabelled choline. 
Standard treatment for intermediate and high risk patients involves several months of neo-
adjuvant hormone therapy. As discussed in the previous chapter, PET/CT scan can be 
performed before hormone therapy (i.e. at staging) which allows delineating of the original 
DIL, or during hormone therapy which allows the CT component to be used for planning. 
There is no published data to suggest if these two schedules produce significantly different 
boost volumes although reduced tracer uptake has been observed in patients who were 
imaged with hormone therapy(206). 
For this chapter, I have retrospectively analysed the PET/CT imaging from the pilot study and 
those that were available from the ongoing BIOPROP20 trial at the time of writing this 
chapter. As will be discussed later in the methods section, this chapter required input from 
consultants and physicists at the Clatterbridge Cancer Centre for DIL delineating and use of 
Aria to obtain DSC data. 
 Aims 
a) To determine whether sizes of DILs identified on 18F choline PET/CT are significantly 
affected by bicalutamide; 
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b) To determine the optimal delineating method for 18F choline PET/CT between visual 
method and threshold method (using 60% of prostate SUVmax). 
 
 Methods 
3.3.1 Study design 
This was a retrospective study using imaging for a cohort of patients who have had both MRI 
(staging mpMRI and planning T2w MRI) and 18F choline PET/CT for prostate dose painting 
radiotherapy planning. Initially patients had PET/CT imaging at planning, whilst on 
bicalutamide (‘with bicalutamide’ group). As visual tracer uptake was noted to be low, 
subsequent patients had PET/CT imaging at staging, before bicalutamide (‘without 
bicalutamide’ group). 
 
3.3.2 Patient selection (inclusion and exclusion criteria) 
Patients had the same eligibility criteria as chapter 2. Of note, the work for the previous 
chapter was performed at a later time point than that of this chapter, thereby accounting 
for the differences in patient numbers. 
Patients who had received 18F choline PET/CT were identified and separated into either the 
‘with bicalutamide’ group or the ‘without bicalutamide’ group. The only difference in the 
planning pathways between the two groups was whether bicalutamide was started before 
or after the PET/CT. In all patients, gold fiducial markers were inserted in the prostate prior 
to PET/CT, planning MRI and planning CT (Figure 3-1). 
88 
 




3.3.3 Imaging protocol 
All patients were scanned with the same PET/CT imaging protocol. Patients were fasted for 
at least four hours prior to imaging and asked to drink 500 ml of water before an intravenous 
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injection of 370 MBq of 18F choline (fluoroethylcholine). A static pelvic scan performed at 90 
minutes post injection in a single bed position over 10 minutes with a GE Discovery 690 
PET/CT scanner (GE Medical Systems, Milwaukee, Wisconsin) was used. Images were 
reconstructed using the iterative line of response (LOR) algorithm. SUV was normalised to 
body weight. 
Prior to the planning T2w MRI and planning CT, patients emptied their bowels with a micro 
enema (Relaxit 5 ml per rectum) and drank 300 ml of water. These scans were acquired with 
an indwelling 12 gauge soft Foley urethral catheter. The planning MRI was performed with 
Turbo Spin Echo thin slice acquisition using a Philips Intera 1.5T MRI scanner with phased 
array coils. The planning CT was performed by a Philips Brilliance wide bore scanner, giving 
a 3 mm slice width. 
3.3.4 DIL delineation protocol 
On ProSoma (OSL Oncology Systems Limited, UK), the PET/CT and planning T2w MRI images 
were rigidly co-registered to the planning CT using the fiducial markers and catheter. The 
whole prostate was delineated on both PET/CT and planning CT. The identification of DILs 
on MRI was performed by two radiation oncologists together by delineating on the planning 
T2w MRI whilst using the staging MRI (anatomical T2w and functional diffusion weighted 
imaging) for reference. The identification of DILs on PET was performed visually (‘visual PET’) 
by the two radiation oncologists on ProSoma, and automatically using a threshold defined 
as 60% of prostate SUVmax (‘threshold PET’) on Mirada (Mirada Medical Limited, UK) where 
SUVmax uptake data was also collected. For standardisation of visual assessments between 
patients, the PET windowing was altered until bone marrow uptake was visually detectable. 
All information was available at time of delineation (including pathology and other imaging). 
3.3.5 Boost volume analysis 
To unite the structures from both ProSoma and Mirada systems, the delineations were 
imported into ARIA version 11 (Varian Medical Systems, USA) which displayed the registered 
images along with all structures. Size data on DIL volumes were collected from ARIA. In order 
to account for registration errors between the primary data set (planning CT) and the 
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secondary data sets (MRI or PET), a 5 mm isotropic expansion margin was performed around 
the DIL delineations (to create the boost volumes) and the prostate delineations within ARIA. 
Correlation analyses were used with these expanded volumes, with four different metrics 
used. Dice similarity coefficient (DSC) was defined according to the following formula (where 
A and B are the volumes of the MRI-defined and PET-defined boosts, and AᴖB is the volume 
of the overlapping boosts): DSC = 2 x AᴖB / (A+B). Sensitivity, specificity and Youden index 
were calculated according to the following formulas (TP (true positive) – overlapping volume 
between MRI and PET boosts; FP (false positive) – PET boost volume excluding the MRI boost 
volume; FN (false negative) – MRI boost volume excluding the PET boost volume; TN (true 
negative) – planning CT prostate delineation excluding both MRI and PET boost volumes): 
Sensitivity = TP / (TP+FN); Specificity = TN / (TN+FP); Youden index = Sensitivity + Specificity 
– 1. 
3.3.6 Statistical analysis 
SPSS V22.0 (International Business Machines Corporation, US) was used for statistical 
analysis. Due to the skewed distribution of the delineation volumes and SUV uptake values, 
they were reported by median and range, with 2-tailed significance testing using Wilcoxon 
signed rank test. As the distribution of the correlation analyses tended to the normal 
distribution (kurtosis were all well below 3 except for DSC between MRI and threshold 
SUV60% PET during bicalutamide which was 3.3), they were reported by mean ± standard 
deviation (SD) with 2-tailed significance testing using independent T test. 
 Results 
There were 11 patients in the ‘with bicalutamide’ group (150 mg once a day orally), and 29 
patients in the ‘without bicalutamide’ group (Table 3-1). 
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Table 3-1 Patient demographics 
*Median and range 
 With bicalutamide Without bicalutamide 
No. of patients 11 29 
Age (years)* 63 (49 – 76) 68 (50 – 77) 
PSA (ng/ml)* 16.6 (10.9 – 28.6) 9.0 (3.6 – 39.4) 
Bicalutamide duration before 
PET/CT (days)* 
85 (42 – 193) - 
High risk † 11 25 
Gleason score 
6 0 1 
7 7 21 
8, 9 4 7 
TNM staging 
T2a 0 5 
T2b, c 4 6 
T3a, b 7 18 
    
 
There was no significant change in prostate volume between PET/CT and planning CT scans 
for the ‘with bicalutamide’ group (median 0.34%, p = 0.48), but there was a significant 




Table 3-2 Prostate and boost volumes 
    With bicalutamide Without bicalutamide 




PET/CT 38.02 30.16 – 44.07 47.02 44.18 – 56.95 
Planning CT 36.92 29.62 – 45.05 39.07 35.68 – 48.94 




MRI 1.98 0.67 – 7.20 2.17 2.07 – 3.77 
visual PET 1.34 0.15 – 3.41 2.62 2.15 – 3.65 
threshold PET 4.81 2.87 – 7.49 3.71 2.81 – 6.31 
      
 
There was a trend for prostate SUVmax to be lower in the ‘with bicalutamide’ group (median 
4.2, range 2.7 to 12.0) compared to the ‘without bicalutamide’ group (median 6.6, range 4.1 
to 18.6) although it did not reach statistical significance (Mann-Whitney U test; p = 0.06). 
In the ‘with bicalutamide’ group, all patients had one MRI DIL, but 3 patients had no visually 
identifiable PET DIL. In the ‘without bicalutamide’ group, 28 patients had at least one MRI 
DIL, one patient had no MRI DIL that could be confidently delineated, and all patients had at 
least one visually identifiable PET DIL(Table 3-3). 
In both groups, the median DILs on MRI were small (1.98 and 2.17 ml), but there was a large 
variation between patients (0.53 – 17.83 ml, Table 3-2). Per individual patient, the visual PET 
DILs were significantly smaller than the MRI DILs in the ‘with bicalutamide’ group (median 
reduction of 63%, p = 0.03) but not in the ‘without bicalutamide’ group (median reduction 
of 5%, p = 0.84)(Table 3-4). The threshold PET DILs were generally larger than the MRI DILs 
in both groups, but this varied between patients and was not statistically significant (median 
increase of 60%, p = 0.33; median increase of 20%, p = 0.19 respectively). 
The correlation analyses showed that both visual and threshold PET have a moderate 
sensitivity (0.50 to 0.68) and a high specificity (0.85 to 0.98) for identifying MRI-defined 
disease (Table 3-4). There was a trend for the PET boost volumes (especially visually defined) 
to correlate better with the MRI boost volumes in the ‘without bicalutamide’ group. 
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Table 3-3 Number of DILs identified 
 n With bicalutamide Without bicalutamide 
No. of patients with n MRI 
DILs 
0 0 1 
1 11 25 
2 0 3 
No. of patients with n visual 
PET DILs 
0 3 0 
1 7 20 
2 1 9 
No. of patients with n 
threshold PET DILs 
0 0 0 
1 10 21 
2 1 6 
3 0 1 
4 0 1 





Table 3-4 Comparison of size and correlation between prostate volumes and boost volumes (with 5 mm 
margin) 
*Mean ± SD 










prostate (+ 5 mm) 
DSC 0.86 ± 0.05 0.86 ± 0.06 - 
MRI vs visual PET 
DIL (+ 5 mm) 
Size comparison 
Paired T test (2-
tailed) 
0.03 0.84  
DSC 0.56 ± 0.11 0.61 ± 0.15 0.41 
Sensitivity 0.50 ± 0.11 0.68 ± 0.18 0.12 
Specificity 0.98 ± 0.03 0.92 ± 0.08 <0.05 
Youden 0.48 ± 0.10 0.60 ± 0.20 0.11 
MRI vs threshold 
PET DIL (+ 5 mm) 
Size comparison 
Paired T test (2-
tailed) 
0.33 0.19  
DSC 0.49 ± 0.15 0.51 ± 0.15 0.72 
Sensitivity 0.64 ± 0.22 0.63 ± 0.25 0.99 
Specificity 0.85 ± 0.14 0.87 ± 0.11 0.63 
Youden 0.48 ± 0.20 0.50 ± 0.21 0.80 






Although the observation of reduced tracer uptake in patients on hormone therapy has 
previously been described, these results have quantified this effect(206). If the PET/CT was 
performed with bicalutamide, the prostate SUVmax was lower although it did not reach 
statistical significance, and over a quarter of patients had no visually identifiable PET DILs 
(Figure 3-2). If the PET/CT was performed without bicalutamide, all patients had at least one 
visually identifiable PET DIL, and two patients had three to four threshold-identified PET DILs. 
These additional volumes tended to be small (0.1 to 0.3 ml) and in practice, would be omitted 
from the total boost volume. 
For the patients who had PET/CT imaging with bicalutamide, visually identified PET DILs were 
similar in size to those seen on MRI, whilst those identified in patients who were imaged 
with bicalutamide were significantly smaller (Figure 3-3 and 3-4). This suggests that choline 
tracer uptake in malignant lesions is reduced by bicalutamide on PET imaging, and therefore 
bicalutamide should ideally be commenced after imaging has been performed. This effect 
might also be found for PET imaging with other tracers such as PSMA, which is increasingly 
used for identifying sites of recurrence following radical treatment. 
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Figure 3-2 Example of a patient who had PET/CT with bicalutamide (left). No DIL could be identified 




Figure 3-3 Example of a patient who had PET/CT (left) with bicalutamide. The DIL identified visually 






Although it would be expected that a similar effect should be found for DILs delineated by 
the threshold PET method, these results have not shown this. This may be because the 
threshold level of SUVmax 60% is too low for our PET imaging protocol, resulting in generally 
larger DILs which may have obscured any effect from bicalutamide. 
Although it did not reach statistical significance, the correlation between threshold PET 
boost volumes and MRI boost volumes were generally poorer than with the visual PET 
method. This is likely to be because clinicians had access to all relevant clinic details at time 
of visual delineation, as per real life clinical practice. The overall DSC values were highest for 
the visual PET in the ‘without bicalutamide’ group (Figure 3-5). 
Our data have also shown that around two and a half months of bicalutamide can reduce 
the overall prostate volume by 17%, albeit with significant inter-patient variation. When 
both PET/CT and planning CT were performed with bicalutamide, the prostate volumes were 
similar although there were differences of up to 7.7% which reflects the difficulty delineating 
pelvic soft tissue on CT. Despite the reduction in prostate size from bicalutamide, the DSC 
between the prostate volumes were the same between the two groups (0.86) which may 
suggest that the variation due to the change in size is on the same scale as the variation due 
to difficulty delineating on CT. Rigid co-registration of the PET/CT and planning CT using the 
fiducial markers and catheter was generally uncomplicated. 
 
 
Figure 3-4 Example of a patient who had PET/CT (left) without bicalutamide. The DIL identified 




Figure 3-5 Distribution of DSC values between (A) MRI and visual PET, (B) MRI and threshold PET (the 




































Ratio of MRI to threshold PET volume




The duration of bicalutamide before PET/CT was performed varied from 42 to 193 days, in 
part due to the busy clinical schedule of the nuclear medicine department. Although it is not 
clear in the literature the duration of bicalutamide at which the effect on prostate volume 
size is maximal, this variability may have influenced volume reduction. The hormone therapy 
used in this study was bicalutamide, an antiandrogen. Other hormone therapies commonly 
used in clinical practice include LHRH agonists which may be expected to have a larger effect 
on SUVmax and boost volume reduction. 
For this study, a standard injected activity of 370 MBq of 18F choline was used, as opposed 
to a dose calibrated to the patient’s weight. This was because when 18F choline PET/CT 
imaging was first introduced in our department, the optimum time of imaging was unclear 
i.e. whether delayed imaging at 90 minutes would be appropriate. Hence, the maximum 
activity possible under the regulations were used. Since this study was conducted, there is 
more evidence for weight based reduction of injected activity which has now been adopted 
within the department. For visual assessment of the static imaging, the windowing could be 
altered to adjust the perceived uptake, and so for consistency the windowing was increased 
until bone marrow uptake was visually detectable. There is no available evidence for the 
optimal window setting for identifying intra-prostatic lesions, although a published paper 
suggested adjusting with the liver as the reference(207). However the liver is not included in 
the pelvic scan, and therefore for consistency, a pragmatic approach was taken to adjust the 
windowing until uptake was seen in the bone marrow. MRI and Nuclear Medicine specialists 
were not directly involved in delineating for this study as radiotherapy delineation is 
principally performed by radiation oncologists in the UK. Therefore these results are directly 
relevant to potential clinical practice. 
There are differing views about the benefit of the addition of 11C choline PET/CT with MRI to 
detect intra-prostatic tumours(39, 208). However Hartenbach et al. showed the increased 
accuracy of using 18F choline PET/MRI (a scanning protocol with a comparatively prolonged 
tracer uptake time) for identifying intra-prostatic tumour compared to MRI alone(52). It may 
be the prolonged uptake time possible with using 18F choline which allows better 
differentiation between malignant and benign prostate tissue. 
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Due to the lack of available literature identifying the optimal threshold level for 18F choline 
PET/CT, the threshold level of SUVmax 60% which was identified by Chang et al. to provide 
the best correlation between 11C choline PET and pathology was used(201). However there 
are key differences between their methodology and that of this study including radioisotope 
used, registration method, and the defined standard (histology vs. MRI) for comparison. 
It is acknowledged that there is a substantial difference in the number of patients between 
the two groups in this retrospective study, and that each group individually constitutes a 
small sample size. However the boost volume correlation methodology deployed here 
followed that in the published work (involving a smaller number of subjects than in either of 
our groups) of Chang et al.(201). 
A limitation of this retrospective study is that the patients were not randomised into the two 
groups, but instead the groups were recruited in sequence from one cohort of patients. This 
should not have resulted in differing group characteristics as the inclusion criteria were 
constant throughout. However, subjective visual identification of DILs may have changed 
over time with increasing experience in analysing choline PET/CT imaging. Furthermore, 
there was a lack of the gold standard comparison with cross-sectional histology. It should be 
noted that surgical series may often include lower risk patients and histology samples distort 
significantly after preparation and mounting. An alternative to cross sectional histology is 
template biopsies, which would have offered an accurate assessment of the location and 
size of significant high grade tumour. Overall, any visual method is by definition subjective, 
and so the conclusions from this study will ideally be confirmed by future studies using 
different PET/CT imaging protocols. Further studies are required to determine whether the 
addition of PET for the planning process will ultimately improve clinical treatment outcomes. 
 Conclusions 
For visual delineation of DILs in prostate dose painting radiotherapy, 18F choline PET/CT 
should be performed before bicalutamide. For threshold delineation of DILs using this 
specific PET/CT scanning protocol, threshold levels of >60% of prostate SUVmax may be more 
suitable. The location and size of PET DILs can vary to that of the MRI boost volumes, and so 
the additional use of PET with MRI for radiotherapy planning can significantly change the 
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overall boost volumes compared to using MRI alone. However, further studies are required 
to determine whether the addition of PET for the planning process will ultimately improve 
clinical treatment outcomes. Similar effects of bicalutamide on PET/CT using other tracers, 
such as PSMA, may exist. 
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4 Planning of moderately hypofractionated dose painting 
radiotherapy for prostate adenocarcinoma 
 
 Introduction 
Whole prostate dose escalation radiotherapy is an effective treatment modality for prostate 
adenocarcinoma but the dose is limited by toxicities. Advanced technology allows delivery 
of highly sculpted inhomogeneous dose distributions with simultaneous dose escalation to 
a boost volume within the clinical target volume (CTV) where there is a higher risk of 
recurrence, whilst still delivering a tumouricidal dose to the rest of the CTV. This 
simultaneous integrated boost (SIB) technique is already standard practice for treating 
prostate and seminal vesicles to different doses. However, studies have shown that it is 
feasible to devise radiotherapy plans with an additional third higher dose level, identified by 
mpMRI, choline PET/CT, or ProstaScint SPECT, although mature biochemical and overall 
survival outcome data are not yet currently available (Table 1-9). Of these studies, only one 
had used the current standard UK prostate dose fractionation schedule of 60 Gy/ 20 #/ 4 
weeks(161). This pilot study of 28 patients was performed at the Clatterbridge Cancer 
Centre, and it showed that delivering a SIB of 68 Gy to the prostatic lesions by rotational 
IMRT with IGRT was feasible within the organs at risk (OAR) constraints and had an 
acceptable safety profile. Therefore a phase II single arm trial (BIOPROP20) was initiated by 
Dr Syndikus (Clinical Oncology Consultant), with recruitment at two UK centres: 
Clatterbridge Cancer Centre and Velindre Cancer Centre.  
For the BIOPROP20 trial, I (together with Dr Syndikus) performed radiotherapy delineating 
for the patients recruited at Clatterbridge Cancer Centre and reviewed the plans created by 





To determine whether prostate dose painting radiotherapy with planning aims of 60 Gy in 20 
# over 4 weeks to the prostate and a SIB of up to 68Gy is likely to meet a level of acceptable 
toxicity before proceeding with a large randomised controlled phase III trial. 
 Methods 
4.3.1 Study design 
This phase II single cohort study (BIOPROP20) aimed to recruit 50 patients which would allow 
an upper limit of 25% of ≥G2 toxicity to be ruled out with a power of 87.8% using the Fleming 
A’Hern design(209). 
4.3.2 Patients selection (inclusion and exclusion criteria) 
Patients had the same eligibility criteria as chapter 2. 
4.3.3 Trial protocol 
All patients who fulfilled the inclusion and exclusion criteria were seen in clinic where the 
options of standard treatment and study treatment were discussed. Patients have already had 
staging pelvic mpMRI at their referring hospitals, with the scanner and sequence used 
depending on local availability and local protocols. Patients were provided with the patient 
information sheets and given at least 24 hours to consider the treatment options. Patients 
subsequently returned to clinic where any outstanding questions were addressed by the 
clinicians, and informed written consent was obtained and patients were registered. 
 
For IGRT, patients received insertion of three gold fiducial markers which was performed 
trans-rectally, assisted by TRUS and under local anaesthetic. Voluntary choline PET/CT was 
offered to patients, and was performed at least 2 weeks after fiducial marker insertions but 
within 4 weeks of patient registration although it could be deferred for logistic reasons. The 
PET/CT imaging protocol has already been described in chapter 3. 
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For those patients who received a choline PET/CT, bicalutamide was commenced after the 
PET/CT (overall duration and choice was at the clinician’s discretion). In general, all 
intermediate risk patients and those with high risk disease localised within the prostate 
received 6 months of oral bicalutamide (150 mg daily). The rest of the high risk patients had 2 
to 3 years treatment with either oral bicalutamide or subcutaneous goserelin (10.8 mg every 
3 months, or 3.6 mg every month). 
Following 2 to 3 months of bicalutamide, patients received planning T2w MRI and planning CT 
scans. The planning scan protocol has already been described in chapter 3. 
In terms of set-up, patients were scanned and treated in the supine position with arms 
positioned outside the radiotherapy field, and immobilisation techniques (knee and ankle 
supports) indexed to the treatment couch were used. Planning scan limits were from bottom 
of the sacro-iliac joints to below the anal margin. If the anterior-posterior diameter of the 
rectum was > 4 cm at any level adjacent to the prostate, the patient was given another micro 
enema and rescanned. 
The choline PET/CT and both planning scans were uploaded into ProSoma (OSL Oncology 
Systems Limited, UK). The planning CT was the primary dataset to which the choline PET/CT 
and planning MRI were rigidly co-registered manually using the fiducial markers and urethral 
catheter. To register planning CT and PET component of the PET/CT, the registration 
parameters between the planning CT and the CT component of the PET/CT (fiducial markers 
were easily defined on CT) were used. To register planning CT and planning T2w MRI, the 
registration parameters between the planning CT and the gradient echo MRI sequence were 
used because the fiducial markers were more difficult to identify in the T2w MRI sequence. 
Delineation was performed by two radiation oncologists; clinical information including prior 
imaging (namely staging mpMRI) and histology reports were available. The prostate and 
seminal vesicles were delineated primarily using the planning MRI whilst referring to the 
planning CT to ensure agreement. The overall DIL volume (GTV3) were defined by combining 
the individual DILs manually delineated by using the MRI and the PET images. A 3 mm margin 
was applied to create the CTV3 within the prostatic tissue, and a further 2 mm margin was 




Table 4-1 CTV and PTV definition and radiotherapy planning aim objectives 
Clinical Target Volume ICRU Planning Target 
Volume 
Dose objectives to ICRU 
Planning Target Volume 
CTV1 
 
Prostate and seminal 
vesicles (including 
disease extending 
outside the prostate) 
PTV1 
 
Margin: CTV1 + 10 mm 
D50% ≥ 53 Gy (median) 
D98% ≥ 50.35 Gy (near 
minimum) 




Prostate and any 
involved seminal vesicle 
(including disease 




Margin: CTV2 + 5 mm 
D50% ≥ 60 Gy (median) 
D98% ≥ 57 Gy (near 
minimum) 
57 Gy isodose should 
encompass PTV2 
CTV2 D50% ≤ 64 Gy 
CTV3 
 
GTV3 + 3 mm, but CTV3 
remains within CTV2 
PTV3 
 
Margin: CTV3 + 2 mm 
 
D50% 60 Gy – 68 Gy 
D2% ≤ 71 Gy 
   
 
Radiotherapy planning software used was Pinnacle3 SmartArc v9.1 (Philips) for a VMAT 
(volumetric modulated arc therapy) plan with two full 6 MV arcs. The median dose to PTV3 
was escalated as much as possible to 68 Gy, allowing for dose constraints to OAR (Table 4-
1). OAR were bladder, rectum, small and large bowel (as a single structure), bilateral femoral 
heads (as a single structure), urethra, and urethral bulb (Table 4-2). Each optimisation was 
recommended to run for 25 iterations. 
For quality assurance, the dosimetry of dose painting radiotherapy plans have previously 
been verified using Delta4 phantom (Scandidos, Sweden) within the pilot study, which had 
used the same dose fractionation, planning and treatment equipment, including 3D 
simulators, software and linear accelerators(161). 
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Whilst the inclusion criteria was for clinically node negative patients on staging pelvic MRI 
imaging, some of the recruited patients were subsequently found to have involved pelvic 
lymph nodes on choline PET/CT. As they remained suitable for radical treatment, they were 
planned for simultaneous prostate and lymph node dose painting radiotherapy: prostate 
was planned as above, with lymph nodes PTV (delineated using a vascular expansion 
technique with a bowel expansion volume as per PIVOTAL study guidelines, and a CTV to PTV 
margin of 5 mm) treated to median dose of 45 Gy and lymph node boost PTV (defined as 
involved nodes with 3 mm margin) treated to median dose of 50 Gy(150). 
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Table 4-2 OAR dose constraints 
 
Organ 






junction and bottom 
of ischial 
tuberosities) 
24.6 70% - 
32.4 60% - 
40.8 50% 60% 
48.6 35% 50% 
52.8 30% 30% 
57.0 15% 15% 
60.0 3% 5% 
64.0 0% 1% 
68.0 0% 0% 
Bowel (including 
small bowel, large 
bowel, and sigmoid 
colon; between 
recto-sigmoid 
junction and 2 cm 
beyond the superior 
extent of CTV1) 
45 78 cc 158 cc 
50 17 cc 110 cc 
55 14 cc 28 cc 
60 0.5 cc 6 cc 
65 0 cc 0 cc 
Urethra (between 
inferior and superior 
ends of PTV1) 




40.8 50% - 
48.6 25% 50% 
60 5% 35% 
Femoral heads (not 
including femoral 
necks) 
40.8 5% 50% 





In total, 57 patients were registered between 14th March 2014 and 15th April 2016 at 
Clatterbridge Cancer Centre. Fifty-five patients had choline PET/CT. Five patients had pelvic 
lymph node positive disease on choline PET/CT, whilst 1 patient had bone metastasis on 
choline PET/CT. Therefore, overall 56 patients had dose painting radiotherapy planning, of 
whom 51 patients had prostate only dose painting and 5 patients had prostate and lymph 
node dose painting radiotherapy planning (Figure 4-1)(Table 4-3). 
Of the 5 patients with pelvic nodal boost volumes, 3 patients had a single node (2 were 
external iliac, 1 was internal iliac) and 2 patients had multiple nodes (one patient had 
ipsilateral nodes involving common iliac and external iliac nodes, and one patient had 
bilateral nodes involving inguinal, internal and external iliac nodes regions). 







Table 4-3 Patient demographics 
* Roach formula for LN risk 
 
    




planning (n = 56) 
Patients with 
prostate only 





dose painting (n 
= 5) 










Age   68 50 - 77 69 56 - 77 66 50 - 77 
Gleason 
6 1    0   1   
7  42   38   4   
8  5   5   0   














T2 18   17   1   
T3a 34   31   3   
T3b 4   3   1   
T4 0   0   0   
Risk 
category 
Intermediate 13   12   1   
High 43   39   4   




18 15 - 40 18 15 - 40 19 15 - 28 
PS 
0 51   46   5   
1 5   5   0   
        
 
4.4.1 Identifying DILs for dose painting radiotherapy 
4.4.1.1 MRI 
The use of both fiducial markers and indwelling catheter for rigid registration between the 
planning CT and planning MRI was uncomplicated. Although the prostate and seminal 
vesicles were predominantly delineated using the planning CT as the primary dataset, the 
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planning T2w MRI was useful in determining the inferior border of the prostate which can 
be difficult to distinguish from the urogenital diaphragm. The DILs were generally identifiable 
on planning MRI with visual reference to the staging MRI. 
4.4.1.2 Choline PET/CT 
Visual assessment of the registration within the choline PET/CT, and between PET and 
planning CT, did not show any significant registration issues for the patients in this study. 
 
4.4.2 Planning 
The overall GTV3 were formed by combining the DILs from both imaging modalities. In order 
to account for delineation uncertainties, expansion margins were used to define the PTV3. 
The median size (and range) of the GTV3 volumes were 3.5 ml (1.2 ml to 14.9 ml) and 4.2 ml 
(6.8 ml to 20.1 ml) for patients receiving ‘prostate only’ and ‘prostate and lymph node’ dose 
painting respectively. The median size (and range) of PTV3 volumes were 13.5 ml (8.2 ml to 
33.1 ml) and 16.3 ml (8.1 ml to 32.0 ml) respectively. 
Planning within the dose constraints was possible for all patients (Tables 4-4 and 4-5). ‘PTV3’ 
is the prostate boost volume; ‘PTV2_PTV3’ is the prostate and involved seminal vesicles 
without the PTV3 boost volume; ‘PTV1_PTV2’ is the prostate and whole seminal vesicles 
without PTV2; ‘PTV LN50’ is the lymph node boost volume; and ‘PTV LN45_LN50’ is the 
lymph node volume without the boost volume. 
For the ‘prostate only’ dose painting group, the median D50% dose achieved to the PTV3 
was 68.1 Gy, and the lowest D50% dose for an individual patient was 66.2 Gy. Of the 51 
patients, 32 (63%) patients had PTV3 D50% of ≥ 68 Gy. 
For the ‘prostate and lymph node’ dose painting group, the median D50% dose achieved to 
the PTV3 was 67.2 Gy, and the lowest D50% dose for an individual patient was 66.8 Gy. Of 
the 5 patients, 1 patient (20%) had PTV3 D50% of ≥ 68 Gy, and all patients had PTV LN50 
D50% of ≥ 50 Gy. 
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Table 4-4 PTV reported doses 
    Planning target 
Prostate only dose painting group 
(n = 51) 
Prostate and lymph node 
dose painting group (n = 5) 
      Median Range Median Range 





D2%  59.24 58.60 - 62.02 59.39 59.00 - 59.99 
D50% ≥ 53.00 56.01 54.98 - 56.96 55.66 55.10 - 55.84 
D90%  53.25 51.99 - 54.03 52.94 52.64 - 53.04 
D98% ≥ 50.35 51.40 50.52 - 52.49 51.51 51.11 - 51.66 
Mean dose  55.83 55.12 - 56.95 55.61 55.17 - 55.74 
Volume (ml)  44.34 35.04 – 85.90 67.00 48.05 - 99.96 
 






D2%  66.37 64.09 - 68.95 66.19 64.68 - 67.62 
D50% ≥ 60.00; ≤ 64.00 61.02 60.39 - 61.67 60.98 60.85 - 61.17 
D90%  59.21 58.37 - 59.76 59.15 58.79 - 59.41 
D98% ≥ 57.00 58.07 57.19 - 59.01 58.03 57.07 - 58.31 
Mean dose  61.37 60.74 - 62.06 61.34 60.98 - 61.45 




          





D50% 60.00 - 68.00 68.10 66.21 - 68.86 67.23 66.79 - 68.46 
D90%  63.81 61.69 - 67.01 63.92 61.38 - 66.42 
D98%  60.93 59.19 - 64.81 62.02 59.52 - 64.57 
Mean dose  67.38 65.96 - 68.45 66.99 66.46 - 67.99 
Volume  13.53 8.22 - 33.10 16.26 8.12 - 32.03 
 




D2%  NA NA 53.16 52.25 - 56.69 
D50%  NA NA 45.22 45.12 - 45.68 
D98%  NA NA 35.69 35.52 - 40.03 
Mean dose  NA NA 45.25 45.15 - 45.77 




          
PTV LN50 (LN 
boost volume) 
D2%  NA NA 53.29 51.51 - 54.67 
D50%  NA NA 51.04 50.13 - 51.39 
D98%  NA NA 48.61 46.36 - 49.04 
Mean dose  NA NA 51.04 50.04 - 51.33 
Volume  NA NA 12.6 8.01 - 30.14 
 
            





Table 4-5 OAR reported doses 
  Optimal planning 
constraints 
Prostate only dose painting group 
(n = 51) 
Prostate and lymph node dose 
painting group (n = 5)  
Median Range Median Range 
Rectum (%) 
V40.8 50% 21.39 13.83 - 42.85 26.34 12.02 - 35.65 
V48.6 35% 15.07 9.09 - 33.32 17.78 6.00 - 18.27 
V52.8 30% 11.29 5.90 - 25.56 10.26 3.08 - 12.40 
V57 15% 4.66 0.29 - 10.43 4.62 0.49 - 5.33 
V60 3% 0.55 0 - 4.66 0.17 0.04 - 1.11 
V64 0% 0 0 - 0.25 0 0 - 0.0 
V68 0% 0 0 - 0 0 0 - 0 
Maximum 
dose  62.36 58.17 - 66.43 62.84 61.64 - 64.62 
Mean dose  21.48 14.99 - 34.32 28.99 23.08 - 33.87 
Volume  51.35 28.93 - 86.43 56.49 43.31 - 88.12 
 
          
Bladder (%) 
V40.8 50% 15.52 4.49 - 43.53 42.21 24.55 - 46.56 
V48.6 25% 19.15 3.05 - 31.87 19.77 9.25 - 26.92 
V60 5% 2.47 0.08 - 6.87 2.39 1.37 - 3.19 
Maximum 
dose  63.59 60.65 - 70.90 64.14 62.52 - 65.38 
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Mean dose  17.48 7.10 – 35.89 39.56 32.47 - 42.18 
Volume  181.07 48.15 - 678.91 167.75 97.01 - 318.58 
 
          
Urethral (%) 
D2% 61 60.44 59.95 - 61.19 60.73 60.17 - 60.79 
Volume  1.77 0.30 - 4.16 2 1.25 - 2.26 
 
          
Bowel (cc) 
V45 78 cc 0 0 – 2.69 2.71 0.1 - 25.1 
V50 17 cc 0 0 – 1.68 0.02 0 - 0.61 
V55 14 cc 0 0 - 0.74 0 0 - 0 
V60 0.5 cc 0 0 - 0 0 0 - 0 
V65 0 cc 0 0 - 0 0 0 - 0 
Maximum 
dose  22.82 1.97 - 58.49 50.9 45.60 - 52.78 
Mean dose  6.56 0.57 – 12.03 20.04 13.02 - 26.38 
Volume  21.81 0.58 - 314.22 447.55 383.84 - 1066.1 
 
          
Femoral heads 
(%) 
V40.8 5% 0 0 - 1.26 0 0 - 7.02 
Maximum 
dose  35.55 27.32 - 43.99 40.2 39.84 - 46.70 
Mean dose  21.91 10.26 - 30.74 27.56 22.37 - 32.13 




Whilst planning within the dose constraints was possible for all patients, the position of the 
boost volumes within the prostate was the main factor that limited the deliverable boost 
dose. During the optimisation, the planning software sometimes struggled as a result of the 
proximity of the OARs (mainly urethra and rectum) and their dose constraints. Extra 
optimisation structures were often required to achieve dose drop off, and superior and 
inferior shells were occasionally required to force superior-inferior dose conformity. 
Overall, more than half of ‘prostate only’ radiotherapy patients achieved a prostatic boost 
dose of ≥ 68 Gy, but only 20% of ‘prostate and lymph node’ radiotherapy patients achieved 
a prostatic boost dose of ≥ 68 Gy whilst all achieved a lymph node boost dose of ≥ 50 Gy.  
Despite the addition of lymph node dose painting radiotherapy, the D50% doses to the 
prostate boost volumes for ‘prostate only’ group (median 68.1 Gy; range 66.2 Gy to 68.9 Gy) 
and for ‘prostate and lymph node’ group (median 67.2 Gy; range 66.8 Gy to 68.5 Gy) were 
not significantly different (Mann Whitney U test, p = 0.09). The BIOPROP20 study also 
recruited at Velindre Cancer Centre, and the D50% doses to the prostate boost volumes of 
the patients recruited there, all of whom were for prostate only dose painting radiotherapy 
(median 65.4 Gy; range 64.0 Gy to 67.6 Gy) were significantly lower to that at Clatterbridge 
Cancer Centre (Mann Whitney U test, p < 0.01). This may be due to differences in experience 
of the radiographers. Velindre Cancer Centre had only planned 5 patients in total, whilst 
Clatterbridge Cancer Centre had planned 56 patients within BIOPROP20 and also had prior 
experience in prostate dose painting from the pilot study. 
For the CHHiP study, one of the treatment arms aimed to deliver 60 Gy for localised prostate 
cancer with three dose levels also(10). These were 60 Gy/ 57.6 Gy/ 48 Gy, compared with 68 
Gy/ 60 Gy/ 53 Gy in the BIOPROP20 study, whilst the high dose volume for CHHiP was the 
whole prostate (60 Gy) compared to DILs (68Gy). There was no posterior margin (CTV3 to 
PTV3) for the high dose volume in CHHiP whilst the maximal extension of the high dose 
volume beyond the boundaries of the prostate in BIOPROP20 was 2 mm, which could lead 
to higher maximum doses in the rectum for BIOPROP20 than for CHHiP. On the other hand, 
margins used for the lower dose levels in CHHiP were 5/10 mm compared to 3/6 mm for 
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BIOPROP20, which could lead to lower median doses in the rectum for BIOPROP20 than for 
CHHiP. From the data presented in this chapter, the median volume of rectum irradiated to 
60 Gy was 0.6%, whilst in CHHiP (for those who had inverse planning) it was 16.0%(210). This 
comparison has to be treated with caution however as the CHHiP data, although published 
in 2019, was for the early cohort of patients treated between 2002 and 2006 using various 
different treatment planning systems and at a time when IMRT was a relatively new 
technique. 
The preceding pilot study for ‘prostate only’ patients, using the same planning aims, was 
reported to have achieved a mean of the PTV68 D50% of 67 Gy (63 to 71 Gy)(161). In the 
current group of ‘prostate only’ patients at Clatterbridge Cancer Centre in the BIOPROP20, 
the median of the PTV68 D50% was 68 Gy. A notable difference between these two studies 
was that the pilot study had used only MRI for DIL delineation, whilst this study had used 
both MRI and PET. However the median DIL volumes were similar (4.3 cm3 and 3.5 cm3 for 
the pilot and this study respectively). 
International Commission on Radiation Units and Measurements (ICRU) Report 83 was 
published to standardise the nomenclature of prescribing, recording, and reporting photon-
beam IMRT, where GTV is defined as “the gross demonstrable extent and location of the 
tumour” and CTV is defined as “a volume of tissue that contains a demonstrable GTV and/or 
subclinical malignant disease with a certain probability of occurrence considered relevant 
for therapy”(211). Whilst it may be argued that the whole prostate outside of the boost 
volume is already being treated with a radical dose which should eliminate subclinical 
microscopic malignant disease and therefore a margin around the DIL to create an intra-
prostatic CTV for the boost volume is not required, we felt it was still reasonable to have a 
margin given that the primary aim of dose painting radiotherapy is to deliver dose escalation 
to the macroscopic DIL for which there is some uncertainty in the accuracy of delineation on 
imaging. 
When MRI has been used to define the prostatic boost volume in previous studies, the 
margins used from the DIL have ranged from 0 mm to 15 mm (Table 4-5). Compared to the 
other studies, Miralbell defined a “tumour-bearing zone” not only on MRI but also used 
information from rectal examination and biopsy specimens(101). This resulted in a 
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sequential boost volume which typically “included the peripheral and central zone tumour-
bearing regions, together with the seminal vesicles if involved” although the sizes of the 
boost volumes were not specified and so it is not known if these volumes would have been 
larger than those of other studies which used imaging alone. When PET has been used to 
define the prostatic boost volume (Wong and Pinkawa), the margins used have ranged from 
0 mm to 4 mm(157, 159). Unlike these other studies, the BIOPROP20 utilised both MRI and 
PET, and so an overall boost margin of 5 mm was used to take into account the additional 
imaging uncertainty that results from subjective visual delineation, image registration and 
effect of bicalutamide on DIL on planning MRI. By referring to the staging mpMRI on another 
monitor at the radiotherapy planning terminal, the malignant nature and size of the 
abnormalities on planning T2w MR imaging were confirmed and the delineations were 
adapted accordingly. This method of visual transfer is subjective but was felt to be 
acceptable given that DILs are given a margin and that the whole prostate is planned to 
receive a radical, albeit lower, dose. 
Table 4-6 Margins used in previous prostate +/- pelvic dose painting studies 
 
Study name 
Prostate boost margin 
Prostate +/- SV 







8 mm from DIL to 
boost volume 
4 mm - - 
Miralbell(101) 
3 mm from tumour-
bearing zone to boost 
volume 
Not specified - Not specified 
FLAME(169) No DIL margin 5 to 8 mm - - 
Wong(157) No DIL margin 6 mm - - 
Sundahl(170) No DIL margin 7 mm - - 
Ippolito(160) 
5 mm from DIL to 
boost CTV 
10 mm margin from 
boost CTV to boost 
PTV (except 8 mm 
posteriorly) 
10 mm margin from 
prostate + SV to PTV 






4 mm margin to boost 
(except 3 mm 
posteriorly) 
8 mm margin 
laterally/anteriorly 
5 mm margin 
superiorly/inferiorly 
4 mm margin 
posteriorly 
- - 
Schild(158) No DIL margin 3 mm margin - - 
Garibaldi(172) Not specified Not specified - - 
Onjukka(161) 
3 mm margin to boost 
CTV 
2 mm margin from 
boost CTV to boost 
PTV 
5 mm margin from 
prostate 
9 mm margin from 
prostate + SV 
- - 
Fonteyne(181) No DIL margin 
7 mm margin from 















Fonteyne(182) No DIL margin 
7 mm margin from 

















When PET has been used to define the pelvic nodal boost volume in previous studies 
(Fonteyne), the margin used from the involved nodes to boost PTV was 7 mm(181, 182). For 
PET node positive patients in the BIOPROP20, the margin used from the involved nodes to 
the boost PTV was 3 mm, in addition to the 5 mm PTV margin for the lower dose elective 
nodal CTV. Therefore a tighter nodal boost margin has been used in BIOPROP20 when 
compared to Fonteyne. Of note, the only other study which treated elective pelvic nodes 
(Miralbell) used a four-field box technique and the specific borders were not described(101). 
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Within the registration process between the planning CT and the PET, there are several 
potential stages where inaccuracies can occur. During PET/CT acquisition, patient movement 
between the PET and CT portions of the scan may result in an intrinsically suboptimal 
registration, and this inaccuracy will then be transferred downstream and incorporated into 
the registration between the PET and planning CT, as the initial step for this registration is 
to match the planning CT with the CT from the PET/CT, where errors can also occur in itself. 
Furthermore, the reduction in prostate volume due to bicalutamide between the PET/CT and 
planning CT may cause registration difficulties, although this reduction is expected to be 
mostly concentric and seem not to result in marked change in fiducial marker position in the 
two dimensional plane. Another factor that may contribute is any difference in bladder filling 
between the scans which can displace the prostate inferiorly, but registration using the three 
fiducial markers embedded within the treatment volume should be able to account for this. 
Despite all these movement uncertainties, the PET/CT and planning CT registration was 
uncomplicated because of the fiducial markers. Of note, a patient with a history of 
transurethral resection of the prostate (TURP) had a dilated bladder neck which led to 
urinary uptake being visualised in the prostate (Figure 4-2). This was confirmed on the MRI. 
Figure 4-2 Figure of PET/CT with TURP 
In this patient with a history of TURP, there is a region of localised tracer uptake within the prostate (right image), but on 





As discussed in chapter 1, there is no consensus in the current published literature as to a 
universally agreed optimum imaging protocol for identifying intra-prostatic lesions on 18F 
choline PET/CT. As experience at Clatterbridge Cancer Centre had shown that uptake 
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appeared visually to be more focal on late imaging, a pragmatic approach was taken to use 
imaging performed 90 minutes following tracer injection. However there were some cases 
with generally diffuse uptake throughout the prostate, and a clinical decision was made for 
the DIL to be delineated at a region of highest visual uptake (Figure 4-3). This was obvious in 
a patient who developed an infection and prostatitis after the fiducial marker insertion.  
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Figure 4-3 Example of generally diffuse choline tracer uptake 
Example of generally diffuse choline tracer uptake throughout the prostate on PET/CT (A) and the PET 







The previous chapter has shown that automatic delineation by using a threshold of SUVmax 
60% produces larger DILs with lower sensitivity and specificity than manually delineation 
when compared with MRI DILs. This suggests that our methodology of using manual 
delineation on the choline PET is more acceptable than using automatic threshold 
delineation. Manual delineation allows the operator more flexibility in defining DILs, but can 
122 
 
increase variability depending on the windowing chosen (Figure 4-4). A pragmatic decision 
was made to adjust the windowing until uptake was seen in the bone marrow before 
delineating. 
According to a large contemporary series, the risk of pathological pelvic lymph node 
involvement in intermediate and high risk prostate cancer patients are 7.2% and 25.5% 
respectively(65). For this group of BIOPROP20 patients with intermediate and high risk 
disease (23.2% and 76.8% respectively), 5 of the 55 staging 18F choline PET/CT scans (9.1%) 
showed radiologically positive pelvic lymph node uptake (Figure 4-5). It is expected that the 
proportion of radiologically detected lymph node involvement is lower than that from 
surgically detected studies because PET/CT imaging has a comparatively lower sensitivity 
than histopathology(212). Another study of intermediate and high risk prostate cancer 
patients found that 19 out of 130 patients (14.6%) had lymph node or bone metastasis on 
18F choline PET/CT(54). Although none of the patients in this group of BIOPROP20 patients 
had bone metastasis detected on 18F choline PET/CT, one patient did have unexpected 
thyroid uptake which led to investigations that confirmed early stage papillary thyroid 




Figure 4-4 Example of varying choline PET windowing 
Before delineation, the windowing is adjusted until uptake is seen in the bone marrow (middle image). The 
















For intermediate and high risk prostate cancer patients, rotational dose painting IMRT 
planning using a moderately hypofractionated schedule of 60 Gy in 20 fractions with an intra-
prostatic boost dose that reached 68 Gy, using a combination of MRI and PET, was achievable 
for more than half of patients. Additional planning with pelvic radiotherapy for involved 
nodal boost dose that reached 50 Gy was achievable for all patients, but led to a reduction 
of prostatic boost dose to less than 68 Gy in most patients.
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5 Acute toxicity of moderately hypofractionated dose 
painting radiotherapy for prostate adenocarcinoma 
 
 Introduction 
For standard radiotherapy, the urethra and base of bladder are included in the prostate PTV, 
and the anterior rectal wall is often close to or included in the prostate PTV. In addition, the 
prostate is a relatively mobile target volume, with the rectum and bladder subject to variable 
filling, movement and deformity (213). Therefore, both acute and late toxicities are 
experienced by a proportion of patients receiving prostate radiotherapy who are generally 
expected to have good long-term survival. With dose painting prostate radiotherapy, the 
addition of a boost volume for dose escalation risks increasing toxicity further. The previous 
chapter demonstrated that it is theoretically feasible to deliver moderately hypofractionated 
dose painting radiotherapy whilst adhering to dose constraints. This chapter will assess the 
acute toxicity of this treatment. 
For prostate cancer, various patient reported outcomes (IPSS, EPIC) and clinician reported 
outcomes (CTCAE, RTOG) have been used in seminal trials(190, 214-216). These validated 
questionnaires can prospectively evaluate symptoms prior to, during, and following 
treatment. Performance status (PS) assesses the ability of the patient to undertake activities 
of daily living, and is used to predict their ability to tolerate treatment and their 
prognosis(217). 
For the BIOPROP20 trial, I (together with Dr Syndikus) recruited and reviewed patients at the 
Clatterbridge Cancer Centre. For this chapter, I have collated and analysed the acute toxicity 
data. 
 Aims 
-To determine the acute toxicities of moderately hypofractionated dose painting 
radiotherapy for prostate adenocarcinoma with 60 Gy in 20 # over 4 weeks and a SIB of up 





For quality assurance, the dosimetry of dose painting radiotherapy plans have previously 
been verified using Delta4 phantom (Scandidos, Sweden) within the pilot study, which had 
used the same dose fractionation, planning and treatment equipment, including 3D 
simulators, software and linear accelerators(161). 
IGRT was delivered using Varian and Elekta linear accelerators with on-board imaging. The 
record and verify system used was Aria (version 11, Varian Medical Systems, USA). Set-up 
verification involved daily online planar orthogonal pair kV imaging (5 cm x 5 cm size) of the 
fiducial markers. All shifts of more than 2 mm were corrected. If shifts of over 1 cm were 
observed, wide field of view CBCT was to be performed. If CTV60 or CTV68 lay outside of 
their PTVs, re-planning was required. 
When patients were registered to the study, baseline assessments were made on CTCAE 
v4.0, RTOG, IPSS, EPIC and PS (Appendix 8.2). Patients were initially assessed with 
LENT/SOMA at the beginning of study recruitment, but EPIC subsequently became standard 
with trial protocol amendment. 
When patients attended for radiotherapy planning (i.e. whilst patients were on bicalutamide 
and before radiotherapy delivery), CTCAE and RTOG were completed again (Figure 5-1). 
During each week of radiotherapy (Week 1, Week 2, Week 3, and Week 4), CTCAE, RTOG, 
and EPIC were completed. 
Six, eight and twelve weeks following commencement of radiotherapy (Week 6, Week 8, and 
Week 12 respectively), CTCAE, RTOG, and EPIC were completed. 
Eighteen weeks following commencement of radiotherapy (Week 18), CTCAE, RTOG, IPSS, 
EPIC, and PS were completed. 
Toxicities up to and including Week 18 were regarded as acute toxicities. Assessments were 
performed within review outpatient clinics, and patients were reassured that the patient 
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reported outcomes data would not affect their clinician’s approach to them or their 
treatments, and so they should answer as honestly as possible. 






















CTCAE * * * * * * * * * * 
RTOG * * * * * * * * * * 
IPSS *         * 
IPSS QoL *         * 
EPIC *  * * * * * * * * 
EPIC patient 
satisfaction *  * * * * * * * * 




5.3.2 Analysis of assessments for acute toxicity 
For CTCAE (in each classification: bladder, lower GI, and toxicities other than urinary and 
lower GI), the number of patients with a G1, G2, G3 and G4 were obtained for each time 
point. This allowed a graph showing the distribution of CTCAE toxicity grade by time point. 
From this, it was possible to show the prevalence of patients with at least a certain toxicity 
value (e.g. G1+ bladder toxicity referred to the proportion of patients with G1 or worse 
bladder toxicity, G2+ lower GI referred to the proportion of patients with G2 or worse lower 
GI toxicity). Furthermore, the prevalence of specific toxicities within each classification were 
shown on a graph at each time point (e.g. G2+ urinary frequency referred to the proportion 
of patients with G2 or worse urinary frequency). 
For RTOG (in each classification: bladder and lower GI), the same analysis was performed. In 
addition, cumulative incidence graphs were created to show the proportion of patients who 
were experiencing or had experienced a certain level of toxicity up to the specific time point 
(for acute toxicity, this was from week 1 to week 18). 
For IPSS, the differences in scores from the time of registration to the time of Week 18 
assessment were calculated, and a waterfall plot was created. A high IPSS score reflected a 
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large amount of urinary symptoms. Therefore when calculating a change in IPSS score 
between these two time points, a negative value reflected improved urinary symptoms, 
whereas a positive value reflected worsened urinary symptoms. As part of the IPSS 
questionnaire, the final question (Question 8: Quality of Life (QoL)) does not contribute to 
the IPSS score itself. Therefore the same analysis was performed specifically for this IPSS 
QoL. The statistical significance of the difference in IPSS scores between registration and 
Week 18 was calculated using related samples Wilcoxon signed rank test. 
For EPIC, domain summary scores were calculated for each of the four categories: Urinary, 
Bowel, Sexual, and Hormonal. Domain-specific subscales were calculated within each of 
these four categories: urinary subscales (function, bother; incontinence, 
irritative/obstructive), bowel subscales (function, bother), sexual subscales (function, 
bother), and hormonal subscales (function, bother). The lower quartile, median, and upper 
quartile values were calculated. If 20% or more of items that comprise the domain summary 
score or subscale score were missing, the corresponding domain summary score or subscale 
score were not calculated(190). 
For PS, the scores were collected at the time of registration and the time of Week 18 
assessment. The prevalence of the scores were calculated for these two time points, and the 
proportion of patients with changes in scores between these two time points were 
calculated. 
 Results 
Fifty-one patients received dose painting radiotherapy to the prostate alone (Figures 5-2 to 
5-12), and five patients received dose painting radiotherapy to the prostate and pelvic lymph 
nodes (Figure 5-13 to 5-23) at the Clatterbridge Cancer Centre. All patients had their first 
fraction between June 2014 and March 2016. Where data was available, non-parametric 
paired analysis was performed between registration and Week 18, and between Week 1 and 
Week 18 (Table 5-1).  
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Figure 5-2 Acute urinary and lower GI CTCAE toxicity by time point for prostate only radiotherapy 





















































































































































































































































































Figure 5-3 Prevalence of specific acute CTCAE toxicities by time point for prostate only radiotherapy 























































































Figure 5-4 Other acute CTCAE toxicities (not urinary or lower GI) by time point for prostate only radiotherapy 












































































































































































































































































































































































Figure 5-5 Prevalence of acute RTOG toxicity by time point for prostate only radiotherapy 










Figure 5-6 Cumulative incidence of acute RTOG toxicity by time point for prostate only radiotherapy 








Figure 5-7 Change in IPSS for prostate only radiotherapy between Registration and Week 18 








































   


































   
   















Figure 5-8 Summary EPIC scores by time point for prostate only radiotherapy 
Urinary summary (A), bowel summary (B), sexual summary (C) and hormonal summary (D). Upper quartile, 























































Figure 5-9 EPIC Urinary subcategories by time point for prostate only radiotherapy 
Urinary function (A), urinary bother (B), urinary incontinence (C), and urinary irritative/obstructive symptoms (D). 





















































Figure 5-10 EPIC bowel subcategories by time point for prostate only radiotherapy 










































Registration Week1 Week2 Week3 Week4 Week6 Week8 Week12 Week18
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Figure 5-11 EPIC sexual subcategories by time point for prostate only radiotherapy 










































Registration Week1 Week2 Week3 Week4 Week6 Week8 Week12 Week18
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Figure 5-12 EPIC hormonal subcategories by time point for prostate only radiotherapy 
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Figure 5-13 Acute urinary and lower GI CTCAE toxicity by time point for prostate and lymph node radiotherapy 
Prevalence (A) and distribution (B) of urinary toxicity grades. Prevalence (C) and distribution (D) of maximal lower 



















































































































































































































































































Figure 5-14 Prevalence of specific acute CTCAE toxicities by time point for prostate and lymph node radiotherapy 














































































Figure 5-15 Other acute CTCAE toxicities (not urinary or lower GI) by time point for prostate and lymph node 
radiotherapy 















































































































































Figure 5-16 Acute RTOG toxicity by time point for prostate and lymph node radiotherapy 






















































































































































































Figure 5-17 Cumulative incidence of acute RTOG toxicity by time point for prostate and lymph node 
radiotherapy 








Figure 5-18 Change in IPSS for prostate and lymph node radiotherapy between Registration and Week 18 








































   


































   
   















Figure 5-19 Summary EPIC scores by time point for prostate and lymph node radiotherapy 
Urinary summary (A), bowel summary (B), sexual summary (C) and hormonal summary (D). Upper quartile, 






















































Figure 5-20 EPIC Urinary subcategories by time point for prostate and lymph node radiotherapy 
Urinary function (A), urinary bother (B), urinary incontinence (C), and urinary irritative/obstructive symptoms (D). 





















































Figure 5-21 EPIC bowel subcategories by time point for prostate and lymph node radiotherapy 
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Figure 5-22 EPIC sexual subcategories by time point for prostate and lymph node radiotherapy 
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Figure 5-23 EPIC hormonal subcategories by time point for prostate and lymph node radiotherapy 
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Table 5-1 Statistical comparisons of symptom scores between registration and week 18, and between week 
1 and week 18 
Comparison for prostate only group using Wilcoxon signed rank test (p values) 
 Registration vs. Week 18 Week 1 vs. Week 18 
PS 0.10 - 
IPSS 
Score 0.83 - 
QoL 0.57 - 
EPIC Patient satisfaction 0.61 0.31 
EPIC summary 
Urinary 0.82 0.02 
Bowel 0.14 0.88 
Sexual <0.01 0.17 
Hormonal <0.01 0.22 
EPIC urinary 
Function 0.58 0.09 
Bother 0.98 <0.01 
Incontinence 0.76 0.48 
Irritative obstructive 0.86 <0.01 
EPIC bowel 
Function 0.39 0.85 
Bother 0.10 0.66 
EPIC sexual 
Function <0.01 0.62 
Bother 0.10 0.09 
EPIC hormonal 
Function <0.01 0.05 
Bother <0.01 0.60 
For the 5 patients who had prostate and lymph node radiotherapy, similar comparisons showed no significant differences for 







Table 5-2 Performance status (PS) within the prostate only radiotherapy group (to week 18) 
Prevalence at registration and week 18 (A), and change in PS between the time points (B) 
A 
   
  Registration Week 18 
  PS 0 PS 1 PS 0 PS 1 
No. of pts  46 5 41 10 





Change in PS from registration to Week 18 No. of patients 
PS 0 to 0 39 
PS 0 to 1 7 
PS 1 to 0 2 
PS 1 to 1 3 
  
  
Table 5-3 Performance status (PS) within the prostate and lymph node radiotherapy group (to 
week 18) 
Prevalence at registration and week 18 (A), and change in PS between the time points (B) 
A 
   
  Registration Week 18 
  PS 0 PS 1 PS 0 PS 1 
No. of pts  5 0 4 1 




Change in PS from registration to Week 18 No. of patients 
PS 0 to 0 4 
PS 0 to 1 1 
PS 1 to 0 0 





5.4.1 CTCAE v4.0 
All patients had CTCAE assessments at each of the 10 time points (510 assessments in total 
for the ‘prostate only’ group, and 50 assessments in total for the ‘prostate and pelvic lymph 
node’ group). 
For the ‘prostate only’ group (Figures 5-2 to 5-4): 
• acute urinary toxicity generally peaked at Week 3, although G2 toxicity continued 
until Week 6. Only one patient experienced G3 toxicity. 
• acute bowel toxicity was generally low, peaking at Weeks 3 and 4. No patients had 
G3 toxicity. 
• other than urinary or bowel categories, the main toxicity was fatigue, with 10% of 
patients with G≥1 fatigue. At Week 18, no patients had fatigue. 
For the ‘prostate and pelvic lymph node’ group (Figures 5-13 to 5-15): 
• acute urinary toxicity peaked at Week 6 where 60% had G2 urinary toxicity. However 
no patients had G2 toxicity thereafter. No patients had G3 toxicity. 
• acute bowel toxicity was generally low, peaking at Week 3. Only one patient 
experienced G2 toxicity. No patients had G3 toxicity. 
• other than urinary or bowel categories, the only toxicity was fatigue, with 20% of 
patients with G1 fatigue. No patients had G2 toxicities. 
 
5.4.2 RTOG 
All patients had RTOG assessments at each of the 10 time points (510 assessments in total 
for the ‘prostate only’ group, and 50 assessments in total for the ‘prostate and pelvic lymph 
node’ group). 
For the ‘prostate only’ group (Figures 5-5 to 5-6): 
• acute urinary toxicity peaked at Week 4. G2 toxicity was experienced by 29%. No 
patients had G3 toxicity. 
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• acute bowel toxicity was generally low, and peaked at Week 4 to Week 6. G2 toxicity 
was only noted in 4%. 
For the ‘prostate and pelvic lymph node’ group (Figures 5-16 to 5-17): 
• acute urinary toxicity also peaked at Week 4. G2 toxicity was experienced by 60%. No 
patients had G3 toxicity. 
• acute bowel toxicity peaked at Week 2 to Week 3. Only 1 patient experienced G2 
toxicity. 
5.4.3 IPSS 
All patients completed the IPSS score at the two time points (102 assessments in total for 
the ‘prostate only’ group, and 10 assessments in total for the ‘prostate and pelvic lymph 
node’ group). 
For the IPSS QoL question, 4 patients in the ‘prostate only’ group did not provide an answer 
at registration but all patients provided an answer at Week 18 (therefore 47 patients had 
QoL values at both time points), whilst 1 patient in the ‘prostate and pelvic lymph node’ 
group did not provide an answer at registration but all provided an answer at Week 18 
(therefore 4 patients had QoL values at both time points). 
For the ‘prostate only’ group (Figure 5-7): 
• There was generally an even distribution between patients who experienced an 
improved IPSS score and patients who experienced a worsened IPSS score, with no 
significant difference between the IPSS scores at registration and at Week 18 (p=0.83; 
Wilcoxon signed rank test). Similarly there was a broadly even distribution between 
patients who experienced an improved IPSS QoL and patients who experienced a 
worsened IPSS QoL (p=0.57; Wilcoxon signed rank test). 
For the ‘prostate and pelvic lymph node’ group (Figure 5-18): 
• There was no significant difference at registration and at Week 18 in both IPSS score 




For the ‘prostate only’ group, EPIC questionnaires were collected from 44 patients at 
registration (for those without EPIC: missing for one patient, and the rest had LENT/SOMA 
as they were registered prior to trial protocol amendment which specified the use of EPIC 
instead). Response rates for the EPIC questionnaires were: all 51 patients at Week 1, 50 
patients at Week 2, 49 patients at Week 3, 48 patients at Week 4, 48 patients at Week 6, 48 
patients at Week 8, 47 patients at Week 12, and all 51 patients at Week 18. Overall, 436 EPIC 
questionnaires were collected out of 459 overall time points (this is excluding the one patient 
who was recruited but subsequently found to be ineligible due to metastatic disease and 
therefore did not receive radiotherapy). 
For the ‘prostate and pelvic lymph node’ group, response rates for the EPIC questionnaires 
were: 4 patients at registration, 5 patients at Week 1, 5 patients at Week 2, 5 patients at 
Week 3, 5 patients at Week 4, 5 patients at Week 6, 4 patients at Week 8, 4 patients at Week 
12, and 5 patients at Week 18. Overall, 42 EPIC questionnaires were collected out of an 
expected 45 questionnaires. 
For the ‘prostate only’ group (Figures 5-8 to 5-12): 
• Urinary summary toxicity and bowel summary toxicity peaked at Week 3 and Week 4 
respectively (urinary function, urinary bother, urinary irritative/obstructive 
symptoms, bowel function, and bowel bother). However there was generally no 
change in urinary continence. Sexual summary and hormonal summary toxicity 
declined between registration and Week 1 as expected from bicalutamide, but 
generally did not change during or up to Week 18. When comparing the EPIC scores 
for registration/Week 1 and EPIC scores for Week 18, there is generally a significant 
worsening of sexual and hormonal toxicity between registration and Week 18, but not 
between Week 1 and Week 18 (Table 5-1). Furthermore, there is generally a 
significant improvement in urinary toxicity between Week 1 and Week 18, but not 
between registration and Week 18 (Table 5-1). However, there is no difference in 
patient satisfaction between the different time points. 
For the ‘prostate and pelvic lymph node’ group (Figures 5-19 to 5-23): 
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• Both urinary summary toxicity and bowel summary toxicity peaked at Week 4. 
However urinary continence was also affected. Sexual summary and hormonal 
summary toxicity declined between registration and Week 1 as expected from 
bicalutamide, and generally did not change during or up to Week 18. Overall, there is 
generally no significant difference in the various EPIC scores and patient satisfaction 
between the different time points (Table 5-1). 
5.4.5 Performance status 
All patients had a PS assessment at the two time points (102 assessments in total for the 
‘prostate only’ group, and 10 assessments in total for the ‘prostate and pelvic lymph node’ 
group). 
In the ‘prostate only’ group, most patients had no change in PS, with 14% had worsening PS 
(Table 5-2). In the ‘prostate and pelvic lymph node’ group, most patients had no change, 
with 1 patient having worsening PS (Table 5-3). 
 Discussion 
Treatment of clinically node-negative prostate cancer with moderately hypofractionated 
dose painting radiotherapy to the prostate alone was well tolerated in terms of acute urinary 
and bowel toxicities according to clinician reported outcomes. Most patients experienced at 
least G1 urinary toxicity, whereas most patients did not experience G1 bowel toxicity. 
However, these toxicities were temporary. As the symptom profile was similar between 
those at registration/planning and those at Week 18, patients recovered from their acute 
toxicities to their pre-radiotherapy state. 
Treatment of clinically node-positive prostate cancer with dose painting radiotherapy to 
both the prostate and pelvic lymph nodes was also generally well tolerated although it was 
more toxic than dose painting radiotherapy to the prostate alone according to clinician 
reported outcomes. Although the cohort size of five patients is small, three patients (60%) 
with dose painting radiotherapy to both prostate and lymph nodes experienced G2 urinary 
toxicity (compared to 30% with dose painting radiotherapy to prostate alone) and this 
peaked at the same time point (2 weeks following completion of radiotherapy). However, 
this was also transient, and no patients experienced G3 toxicity. Prevalence of bowel toxicity 
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was higher for dose painting radiotherapy to both prostate and lymph nodes, with G2 
toxicity of around 20% (compared to 5% with dose painting radiotherapy to prostate alone). 
This would be expected due to increased mean and maximal doses to the bowel and bladder 
as shown in radiotherapy planning dosimetry data in the previous chapter. No patients had 
G2 bowel toxicity at Week 18 in either group. 
From the patient reported outcomes, the IPSS scores also suggest that urinary symptoms do 
not worsen for the patients as a group between registration and Week 18 (i.e. from 
treatments with both bicalutamide and dose painting radiotherapy). However the EPIC 
scores show a small, but statistically significant, improvement in the urinary categories 
between Week 1 and Week 18 in the prostate only group. This should be interpreted with 
caution, as the patients may have already started to experience toxicity at Week 1, although 
unlikely, and hence cannot be regarded as patients experiencing improved urinary toxicity 
due to dose painting radiotherapy. In retrospect, it would have been informative to have 
EPIC data collected at planning, together with the CTCAE and RTOG data. With the EPIC data 
available to compare symptoms at registration and Week 18, patients did not experience 
residual urinary or bowel toxicity following the acute phase from both bicalutamide and dose 
painting radiotherapy. In comparison, patients did experience significant sexual and 
hormonal toxicity, primarily from bicalutamide (rapid reduction in EPIC scores between 
registration and Week 1), and this did not generally deteriorate from the subsequent dose 
painting radiotherapy. 
One of the CHHiP treatment arms involved delivering 60 Gy/20 #/4 weeks for localised 
prostate cancer(10, 98). It aimed to deliver three dose levels also ([60 Gy/ 57.6 Gy/ 48 Gy] 
vs. [68 Gy/ 60 Gy/ 53 Gy]), but the high dose volume was the whole prostate (60 Gy) as 
opposed to the DILs (68 Gy). In addition, no posterior margin for the high dose volume (from 
CTV3 to PTV3) was used within CHHiP, whilst the maximal extension of the high dose volume 
beyond the boundaries of the prostate within the BIOPROP20 protocol was 2 mm. Additional 
margins for the lower dose levels used in CHHiP were 5/10 mm, compared to 3/6 mm for 
BIOPROP20. The inclusion criteria for CHHiP allowed for lower risk disease when compared 
to BIOPROP20 (T1b-T3a compared to T2a-T4; PSA ≤ 30 ng/ml compared to no upper limit; 
estimated risk of lymph node involvement of < 30% compared to <40%), with only 8% of 
their patients having T3 disease compared to 67% in this study. In terms of treatment 
delivery for CHHiP, static-field IMRT was used and IGRT techniques with 3 mm tolerance 
were permitted although not required (was used in 30% of patients). In comparison for 
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BIOPROP20, rotational IMRT was used and IGRT technique with fiducial markers and 2 mm 
tolerance were standard for all patients. 
Despite these notable differences in trial protocol between the CHHiP and BIOPROP20 
studies and hence a direct comparison cannot be drawn, the acute RTOG toxicity profiles for 
prostate only dose painting patients who received a SIB to 68 Gy did not seem to be 
significantly higher than those who received homogenous prostate radiotherapy of 60 Gy/20 
#(10). Bowel and bladder toxicity peaked at weeks 4 to 5 in CHHiP, whilst it peaked at weeks 
4 to 6 in this study. Cumulative incidence of patients who reported RTOG G2 or worse bowel 
toxicity in CHHiP was 38%, compared to 6% in this study. Cumulative incidence of patients 
who reported RTOG G2 or worse bladder toxicity in CHHiP was 49%, compared to 55% in this 
study. Prevalence of RTOG G2 or worse bowel toxicity at week 18 in CHHiP was 3%, 
compared to 0% in this study. Prevalence of RTOG G2 or worse bladder toxicity at week 18 
in CHHiP was 5%, compared to 12% in this study. Therefore, the main difference is actually 
reduced bowel toxicity in this study compared to CHHiP, which may be explained by the 
routine use of IGRT with fiducial markers and tighter set-up tolerance in the BIOPROP20 
protocol than in the CHHiP protocol. 
There are limitations to this study and the analysis made. Patients were encouraged to 
complete the EPIC forms fully, but some patients did not answer enough questions in the 
sexual categories to allow a score to be calculated (for instance, 23 out of 56 of all included 
patients did not have an EPIC sexual summary score at the Week 18 time point). This may be 
due to significantly reduced sexual activity as a result of the treatment, although the answer 
options available still allowed patients to provide an answer for this. Also, not all the 
symptoms/toxicity scores were performed at every time point (Figure 5-1). This was with the 
purpose of improving patient compliance and response rates for questionnaire completions, 
especially as the EPIC questionnaire is 9 pages in total. But as discussed above, it would have 
been of interest to have obtained EPIC data at planning, to allow differentiation between 
bicalutamide and radiotherapy as the cause of patient reported urinary toxicity. Also 
performing multiple statistical comparisons, in this case between different time points for 
the various EPIC subcategories, can result in erroneous inferences (Table 5-1). However, the 




Generally, it is preferable to obtain both patient reported and clinician reported outcomes, 
given that patient reported outcomes may detect toxicities more reliably that clinician 
reported outcomes(218, 219). But there are some considerations to be made. For patient 
reported questionnaires, patients may feel obliged to report less severe toxicities. For 
clinician reported questionnaires, reporting of symptomatic adverse events can be 
unreliable and clinicians often under-report the incidence and severity of 
symptoms/toxicities compared to patients(220). However, although not directly 
comparable, the peak toxicities of the CTCAE/RTOG and the EPIC scores are in general 
agreement in this study. 
Overall, the phase II BIOPROP20 study aimed to recruit 50 patients at both Clatterbridge 
Cancer Centre and Velindre Cancer Centre in order to rule out an upper limit of G≥2 toxicity 
of 25% (with power of 87.8%). According to the Fleming-A’Hern design, if 8 or more patients 
developed G≥2 toxicity at week 18, the null hypothesis will not be rejected (i.e. the 25% 
upper limit is not ruled out). Although the analysis of this chapter consisted of the 51 patients 
treated with prostate only dose painting radiotherapy at Clatterbridge Cancer Centre alone, 
7 patients had G≥2 urinary toxicity at week 18 (CTCAE) and no patients had G≥2 bowel 
toxicity. The final statistical analysis for the whole of the BIOPROP20 study is currently 
pending. 
 Conclusion 
Acute toxicity of moderately hypofractionated dose painting radiotherapy for prostate 




6 Late toxicity of moderately hypofractionated dose painting 
radiotherapy for prostate adenocarcinoma  
 
 Introduction 
Although the previous chapters show that dose painting radiotherapy is feasible and appears 
well tolerated in the acute setting, longer term follow up is required to assess late toxicity. 
This is important given that prognosis is generally good for locally advanced prostate cancer, 
with patients often surviving for years even with metastatic disease as a result of the 
increasing number of effective palliative treatment options available. For instance in a recent 
STAMPEDE paper which reported outcomes from the up-front addition of abiraterone and 
docetaxel for patients with either high risk non-metastatic disease or metastatic disease, 
median survival had not been reached despite a median follow up of 4 years(221). 
Total follow up of patients within the BIOPROP20 study was for 2 years. For the Clatterbridge 
Cancer Centre patients, I (together with Dr Syndikus) reviewed patients up to their 2 year 
follow up time point. I have collated and analysed the late toxicity data. 
 
 Aims 
- To determine the late toxicities of moderately hypofractionated dose painting 
radiotherapy for prostate adenocarcinoma with 60 Gy in 20 # over 4 weeks and a SIB 
of up to 68 Gy. 
 
 Methods 
Patients were reviewed at 6 months, 12 months, 18 months and 24 months following 
commencement of radiotherapy. At all of these time points, PSA levels, CTCAE toxicity score, 
RTOG toxicity score, and IPSS scores were collected. At the 24 months follow up, additional 
161 
 
data were collected for physical examination and performance status. Acceptable time 
intervals for assessments to be performed were within 3 months of the expected date of 
completion (as per the CHHiP protocol). 
The toxicity scores were analysed and presented as per Chapter 5. For RTOG cumulative 
incidence graphs, the late toxicity time frame was from month 6 to month 24. After the last 
patient had reached 24 months follow up, data on survival and PSA relapse at the latest 
follow up were collected for all patients. 
 
 Results 
Of the 51 patients who received dose painting radiotherapy to the prostate alone, one had 
died of myocardial infarction before 2 year follow up was reached (his last PSA was 0.1 at 
month 18, and he was still on hormone therapy with no evidence of disease recurrence). At 
2 year follow up, 6 of the 50 surviving patients were on adjuvant hormone therapy (12%) 
and 1 had biochemical relapse (2%) with PSMA scan showing local as well as distant 
metastatic disease. 
Of the 5 patients who received dose painting radiotherapy to the prostate and pelvic lymph 
nodes, all were alive at 2 year follow up, at which point 3 patients were on adjuvant hormone 
therapy (60%) and none had biochemical relapse (0%). 
 
6.4.1 CTCAE v4.0 
All patients had CTCAE assessments at each of the four time points except the patient who 
had assessments at three time points and died before 2 year follow up (203 assessments in 
total for the ‘prostate only’ group, and 20 assessments in total for the ‘prostate and pelvic 
lymph node’ group). 
For the ‘prostate only’ group (Figures 6-1 to 6-3): 
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• Late urinary toxicity was generally static without significant change from month 6 to 
month 24 follow up. G2 toxicity was reported for 6% of patients at month 24. No 
patients had G3 urinary toxicity. 
• Late bowel toxicity was generally low. G2 toxicity was reported for 2% at month 24. 
No patients had G3 bowel toxicity. 
• Other than urinary or bowel categories, toxicities were rare and those reported were 
gynaecomastia and groin pain. 
For the ‘prostate and pelvic lymph node’ group (Figures 6-8 to 6-10): 
• Late urinary toxicity of G1 was experienced by 60% but no patients had G2 at month 
24.  
• Late bowel toxicity of G1 was experienced by 40% but no patients had G2 at month 
24. 
• Other than urinary or bowel toxicity, the only toxicity noted was G2 mood changes 
in one patient. 
 
6.4.2 RTOG 
All patients had RTOG assessments at each of the four time points except the patient who 
died before 2 year follow up (203 assessments in total for ‘prostate only’ group, and 20 
assessments in total for the ‘prostate and pelvic lymph node’ group). 
For the ‘prostate only’ group (Figures 6-4 to 6-5): 
• Late urinary toxicity was generally static. G2 toxicity was reported for 6% of patients 
at month 24. No patients had G3 toxicity. 
• Late bowel toxicity was rare with G2 toxicity reported for only 2%. No patients had 
G3 bowel toxicity. 
For the ‘prostate and pelvic lymph node’ group (Figure 6-11 to 6-12): 




• Late bowel toxicity of G1 was experienced by 20%, but no patients had G2 at month 
24. 
6.4.3 IPSS 
All patients completed the IPSS score except one ‘prostate only’ patient at month 6, one 
‘prostate only’ patient at month 18, and the patient who had died before 2 year follow up 
(201 assessments in total for the ‘prostate only’ group, and 20 assessment in total for the 
‘prostate and pelvic lymph node’ group). 
For the IPSS QoL question, one patient did not submit a score at month 6, two patients at 
month 18, and two patients (including the patient that had died) at month 24. These were 
all patients in the ‘prostate only’ group. There was no missing data in the ‘prostate and pelvic 
lymph node’ group (therefore 199 assessments in total for the ‘prostate only’ group and 20 
assessments in total for the ‘prostate and pelvic lymph node’ group).  
For the ‘prostate only’ group (Figures 6-6 to 6-7): 
• IPSS scores were generally stable between month 6 and month 24 for the group as 
a whole, and there was no significant difference between the IPSS scores at 
registration and at month 24 (p = 0.26; Wilcoxon signed rank test). This was similar 
for the IPSS QOL scores also (p = 0.26; Wilcoxon signed rank test). 
For the ‘prostate and pelvic lymph node’ group (Figures 6-13 to 6-14): 
• There appears to be a trend for a consistent rise in IPSS score for the whole group 
between month 6 and month 24 but there was no significant difference between 
the IPSS score at registration and at month 24 (p = 0.07; Wilcoxon signed rank test). 
IPSS QOL scores appeared stable between month 6 and month 24, and there was no 
difference at all between the IPSS QOL scores at registration and at month 24 (p = 
1.00; Wilcoxon signed rank test). 
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6.4.4 Performance status 
All patients had a PS assessment at registration and at month 24 except for the patient who 
died before 2 year follow up (101 assessments in total for the ‘prostate only’ group, and 10 
assessments in total for the ‘prostate and pelvic lymph node’ group). 
In the ‘prostate only’ group, most patient remained at PS 0 (38 out of 50), 8 patients (16%) 
had a deterioration in PS, but there was no significant change in PS between registration and 
month 24 (p = 0.05; Wilcoxon signed rank test)(Table 6-1). In the ‘prostate and pelvic lymph 
node’ group, all patients remained at PS 0 (p = 1.00; Wilcoxon signed rank test)(Table 6-2). 
6.4.5 Treatment outcome 
After the last living patient had reached 2 year follow up, survival and PSA data at the last 
follow up for each patient was collected on 30th November 2018. Median follow up was 36 
months (range 20 to 49 months, including the patient who died before 2 year follow up). 
Of the 56 patients, 3 (all had prostate only dose painting radiotherapy) had died of causes 
unrelated to the prostate adenocarcinoma (myocardial infarction and oesophageal 
adenocarcinoma); they did not have PSA relapse at their last follow up (Figure 6-15). Two 
patients had PSA relapse (by Phoenix criteria), both of which were following completion of 
adjuvant hormone therapy (Figure 6-16). One of these patients (he had received prostate 
and lymph node treatment) was found to have bone metastasis for which he was 
recommenced on hormone therapy together with zolendronic acid. The other patient (he 
had received prostate only treatment) was found to have bone and nodal metastasis, and 
was initially recommenced on hormone therapy alone but subsequently progressed and so 
received docetaxel, palliative radiotherapy, and now starting enzalutamide.  Of those 




Figure 6-1 Late urinary and lower GI CTCAE toxicity by time point for prostate only radiotherapy 





































































































Figure 6-2 Prevalence of specific late CTCAE toxicities by time point for prostate only radiotherapy 






































































Figure 6-3 Other late CTCAE toxicities (not urinary or lower GI) by time point for prostate only 
radiotherapy 
























































































Figure 6-4 Late RTOG toxicity by time point for prostate only radiotherapy 

















































































































Figure 6-5 Cumulative incidence of late RTOG toxicity by time point for prostate only radiotherapy 








Figure 6-6 IPSS score (A) and IPSS Quality of Life score (B) between registration and month 24 for 
prostate only radiotherapy 





































Figure 6-7 Change in IPSS for prostate only radiotherapy between registration and month 24 








































































Figure 6-8 Late urinary and lower GI CTCAE toxicity by time point for prostate and lymph node 
radiotherapy 

















































































































Figure 6-9 Prevalence of specific late CTCAE toxicities by time point for prostate and lymph node 
radiotherapy 






































































Figure 6-10 Other late CTCAE toxicities (not urinary or lower GI) by time point for prostate and lymph 
node radiotherapy 




























































































Figure 6-11 Late RTOG toxicity by time point for prostate and lymph node radiotherapy 







































































































Figure 6-12 Cumulative incidence of late RTOG toxicity by time point for prostate and lymph node 
radiotherapy 








Figure 6-13 IPSS score (A) and IPSS Quality of Life score (B) between registration and month 24 for 
prostate and lymph node radiotherapy 





































Figure 6-14 Change in IPSS for prostate and lymph node radiotherapy between registration and 
month 24 








































































Table 6-1 Performance status (PS) within the prostate only radiotherapy group (to month 24) 
Prevalence at registration and month 24 (A) and change in PS between the time points (B) 
 
A 
 Registration Month 24 
 PS 0 PS 1 PS 0 PS 1 PS 2 Unanswered 
No. of pts 46 5 40 8 2 1 
 
B 
Change in PS from 
Registration to Month 24 
No. of patients 
PS 0 to 0 38 
PS 0 to 1 6 
PS 0 to 2 1 
PS 1 to 0 2 
PS 1 to 1 2 
PS 1 to 2 1 




Table 6-2 Performance status (PS) within the prostate and lymph node radiotherapy group (to month 
24) 
Prevalence at registration and month 24 (A) and change in PS between the time points (B) 
 
A 
 Registration Month 24 
 PS 0 PS 1 PS 0 PS 1 
No. of pts 5 0 5 0 
 
B 
Change in PS from 
Registration to Month 24 
No. of patients 
PS 0 to 0 5 
PS 0 to 1 0 
PS 1 to 0 0 





Figure 6-15 Kaplan Meier Curve for Overall Survival for all 56 patients 
Three patients had died (at 20 months, 34 months, and 36 months)  
 
 
Figure 6-16 Kaplan Meier curve for PSA relapse (by Phoenix criteria) for all 56 patients 






Treatment of clinically node-negative prostate cancer with moderately hypofractionated dose 
painting radiotherapy to the prostate alone was well tolerated and toxicity generally did not worsen 
from month 6 to month 24. Prevalence of late G≥2 urinary toxicity was around 6% and was mostly 
urinary frequency. Prevalence of late G≥2 bowel toxicity was around 2% and was mostly diarrhoea. 
Only 16% had a deterioration in performance status between registration and month 24. 
Treatment of clinically node-positive prostate cancer with dose painting radiotherapy to both the 
prostate and pelvic lymph nodes was also well tolerated. No patients had late G≥2 urinary or bowel 
toxicity. The commonest urinary toxicity reported was retention and urgency, and the commonest 
bowel toxicity reported was diarrhoea and rectal haemorrhage. IPSS score showed an increase from 
month 6 to month 24 but there was no statistically significant difference between registration and 
month 24 (of note, an IPSS score of <12 is classed as no or mildly symptomatic only). In comparison, 
the IPSS QOL score was stable, and there was no deterioration in performance status between 
registration and month 24. 
In comparison to the pilot study, the cumulative incidence of late G≥2 toxicities for prostate only 
dose painting radiotherapy were higher in this study for both urinary (20% vs. 7%) and bowel (4% vs. 
0%) toxicities(161). This may be due to fundamental differences between the studies. The 
BIOPROP20 protocol offered the addition of 18F choline PET/CT to aid DIL delineation whilst the pilot 
study did not, but this did not result in larger DILs (median 3.5 ml (range 1.2 ml to 14.9 ml) for this 
study vs. median 4.3 ml (range 0.46 ml to 15 ml) for the pilot study). The pilot study used a research 
version of Pinnacle in order to create plans radiobiologically optimised for tumour control 
probability and normal tissue complication probability as the first step, before re-planning in the 
clinical treatment planning system whilst attempting to reproduce certain planning parameters from 
the radiobiologically optimised plan. The mean (and range) of the maximum doses to the rectum 
achieved by the clinical plans in the pilot study were 56 Gy (53 to 58 Gy), whilst that of this study 
were 62 Gy (58 to 66 Gy). Therefore this may explain the higher bowel toxicities in this study when 
compared to the pilot study, although care needs to be taken when comparing outcomes from 
separate studies with small sample numbers. 
In comparison to the CHHiP study, the prevalence of G≥2 RTOG late bladder toxicity at 2 year follow 
up was higher in this study (6% vs. 2%) but was similar for late bowel toxicity (2% vs. 3%)(10). 
According to the Fleming-A’Hern design for the BIOPROP20 study which aimed to recruit 50 patients, 
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if 7 or less patients developed G≥2 toxicity at 2 years, the null hypothesis will be rejected in favour of 
a 10% complication rate. Although the analysis of this chapter consisted of the 51 patients treated 
with prostate only dose painting radiotherapy at Clatterbridge Cancer Centre alone, 3 patients had 
G≥2 urinary toxicity at 2 years (CTCAE and RTOG) and 1 patient had G≥2 bowel toxicity (CTCAE and 
RTOG). The final statistical analysis for the whole of the BIOPROP20 study is currently pending. 
In terms of disease control, 1 patient out of 51 patients (2%) who received prostate only dose 
painting radiotherapy in this study had biochemical failure by 2 years follow up, whilst 88 out of 
1074 patients (8%) who received prostate only radiotherapy in the CHHiP study (60 Gy arm) had 
biochemical or clinical events by 5 years follow up. This suggests that disease control with dose 
painting is acceptable at this relatively short follow up time interval, which would be expected given 
that dose painting should theoretically increase disease control +/- toxicities. 
 Conclusion 
Late toxicity (up to 2 years follow up) for moderately hypofractionated dose painting radiotherapy for 
prostate adenocarcinoma appears to be well tolerated and clinically acceptable.  
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7 Future directions 
Current standard of care non-surgical treatment for intermediate and high risk localised or 
locally advanced prostate cancer is a combination of hormone therapy and radiotherapy, 
where radiotherapy involves the delivery of a homogenous dose to the whole gland 
irrespective of the pattern of disease within it. Modern technological advances in imaging 
technology allow the identification of dominant intraprostatic lesions where there is highest 
risk of local recurrence, and advances in radiotherapy delivery allow dose escalation to sub-
volumes within the target volume. Given that whole organ dose escalation radiotherapy 
leads to improved biochemical control at a cost of increased toxicity, selective dose 
escalation by dose painting to these sub-volumes responsible for local failure may lead to 
improved disease control without a significant increase in toxicity. 
This thesis shows that planning and delivery of moderately hypofractionated dose painting 
radiotherapy to the prostate appear to be both feasible and clinically acceptable with 
regards to toxicity. However, the data presented here are for 2 years follow up, and given 
that prognosis is generally good for this group of patients, longer term data is required to 
assess clinical outcomes including biochemical relapse free survival and overall survival, and 
to assess for any emergent late toxicity beyond 2 years follow up. Also only 5 patients were 
treated with both prostate and pelvic nodal radiotherapy, and although the results show 
that it is technically feasible, larger cohorts will need to be treated in order to allow 
conclusions to be drawn regarding toxicity. 
Dose escalation by external beam radiotherapy is limited by dose to the surrounding organs. 
HDR brachytherapy provides an alternative method of radiation delivery and although it is 
an invasive procedure with the associated risks of general anaesthesia, it provides better 
dose conformity and can deliver higher biologically effective doses. Therefore dose painting 
by using a combination of external beam radiotherapy and HDR brachytherapy may offer an 
improved therapeutic ratio. 
For radiotherapy planning, the dose descriptors of organs at risk, including bladder and 
rectum, are based on dose volume histograms. However, these methods lose spatial dose 
information, and advanced methods such as bladder and rectal dose surface maps would 
preserve dose distribution data. This may be more useful when assessing plans for dose 
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painting radiotherapy, as the heterogeneous dose distributions generated can involve focal 
hot spots with high dose gradients in close proximity to surrounding organs at risk. 
With regards to imaging to define the dominant intraprostatic lesions, this thesis has used 
18F choline tracer for PET/CT imaging. With the increasing availability and utilisation of PSMA 
PET/CT, there is strong evidence for its use in identifying disease recurrence after definitive 
treatment. It would be of interest to investigate whether PSMA performs better than 18F 
choline in localising dominant intraprostatic lesions for dose painting. 
The work contained in this thesis has led to the PIVOTALboost trial which is currently 
underway. It is a large national multicentre randomised phase III clinical trial for dose 
painting radiotherapy, where patients with node negative intermediate risk (with at least 2 
adverse features including maximum tumour length >6mm, ≥50% biopsy core positive and 
>50% involved cancer/total biopsy length) or high risk prostate cancer are randomised to 
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 Risk stratification for prostate cancer (NCCN guidelines 2018) 
Risk group Clinical/Pathological features 
Very low All of the following: 
- T1c 
- Gleason ≤ 6 / grade group 1 
- PSA < 10 ng/ml 
- < 3 prostate biopsy fragments/cores positive, ≤50% cancer in each 
fragment/core 
- PSA density < 0.15 ng/ml/g 
Low All of the following: 
- T1 – T2a 
- Gleason score ≤ 6 / grade group 1 
- PSA < 10 ng/ml 
Intermediate - 
favourable 
Any of the following: 
- T2b – T2c 
- Gleason score 3 + 4 = 7/ grade group 2 
- PSA 10 – 20 ng/ml 
PLUS percentage of positive biopsy cores < 50% 
Intermediate - 
unfavourable 
Any of the following: 
- T2b – T2c 
- Gleason 3 + 4 = 7/ grade group 2 or Gleason 4 + 3 = 7/grade group 3 
- PSA 10 – 20 ng/ml 
High Any of the following: 
- T3a 
- Gleason score 8 / grade group 4 or Gleason 4+5 = 9/ grade group 5 
- PSA > 20 ng/ml 
Very high Any of the following: 
- T3b – T4 
- Primary Gleason pattern 5 
- > 4 cores with Gleason score 8 – 10/ grade group 4 or 5 
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 Assessment forms 
9.2.1 CTCAE 
CTCAE 1 2 3 4 




































limiting self care 
ADL 
- 




limiting self care 
ADL 
- 
Diarrhoea Increase of <4 
stools per day 
over baseline; 




Increase of 4 – 6 







Increase of ≥7 

































































































































































indicated; able to 






































RTOG 1 2 3 4 
Lower GI Increased 
frequency or 
change in quality 










Lomotil) / mucous 
discharge not 
necessitating 








support / severe 
mucous or blood 
discharge 
necessitating 































nocturia which is 












pain or bladder 
spasm requiring 
regular, frequent 
narcotic / gross 
haematuria with 















IPSS Not at all 
Less than 1 



















0 1 2 3 4 5 
Frequency: 
How often 
have you had 
to urinate less 
than every 
two hours? 










0 1 2 3 4 5 
Urgency: How 
often have 




0 1 2 3 4 5 
Weak stream: 
How often 




0 1 2 3 4 5 
Straining: 
How often 
have you had 
to strain to 
start 
urination? 
0 1 2 3 4 5 
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 None 1 time 2 times 3 times 4 times 5 times 
Nocturia: 
How many 
times did you 
typically get 
up at night to 
urinate? 
0 1 2 3 4 5 
 
9.2.4 IPSS QoL 







Quality of life 
due to urinary 
symptoms: If 
you were to 
spend the rest 




the way it is 
now, how 
would you feel 
about that? 
0 1 2 3 4 5 6 
 
9.2.5 PS 
Performance Status Criteria 
0 
Able to carry our all normal activity without 
restriction 
1 
Restricted in strenuous activity but 
ambulatory and able to carry out light work 
2 
Ambulatory and capable of all self-care but 
unable to carry out any work activities; up and 
about more than 50% of waking hours 
3 
Symptomatic and in a chair or in bed for 
greater than 50% of the day but not bedridden 
4 
Completely disabled; cannot carry out any 

































9.2.7 Publications and Presentations 
Is choline PET useful for identifying intraprostatic tumour lesions? A literature review 
Chan J, Syndikus I, Mahmood S, Bell L, Vinjamuri S. 










































Effect of androgen deprivation therapy on intraprostatic tumour volume identified on 
18F choline PET/CT for prostate dose painting radiotherapy 
Chan J, Carver A, Brunt JNH, Vinjamuri S, Syndikus I 





























Hypofractionated dose painting IMRT for intermediate to high risk localised prostate 
cancer: treatment with 20 fractions 
Chan J, Rowntree T, Brunt J, Howard L, Syndikus I. 






Hypofractionated dose painting IMRT using 20 fractions for intermediate and high-risk 
localised prostate cancer: Two-year outcome data (BIOPROP20, NCT02125175) 
Syndikus I, Chan J, Rowntree T, Howard L, Staffurth J 









June 2015 Dose painting radiotherapy for high risk prostate cancer: delayed 18F-choline 
PET/CT imaging before neo-adjuvant hormone therapy improves detection 
rates 
 Chan J, Mahmood S, Brunt J, Vinjamuri S, Syndikus I.  
 Biology-Guided Adaptive Radiotherapy 13th Acta Oncologica Symposium 




 June 2017 Hypofractionated dose painting IMRT for intermediate to high risk prostate 
cancer: treatment with 20 fractions 
 Chan J, Jackson R, Rowntree T, Brunt J, Howard L, Syndikus I.  









Feb 2019 Hypofractionated dose painting IMRT using 20 fractions for intermediate to 
high risk localised prostate cancer: 2 year outcome data 
 Syndikus I, Chan J, Rowntree T, Howard L, Staffurth J 
 GU ASCO 2019 
 
May 2017 Impact of 18F choline PET scan acquisition time on delineation of GTV in 
prostate cancer 
 Parkinson C, Chan J, Syndikus I, Marshall C, Staffurth J, Spezi E 
 ESTRO 2017 
 
Sept 2016 Hypofractionated dose painting IMRT for intermediate to high risk localised 
prostate cancer: treatment with 20 fractions 
 Chan J, Rowntree T, Brunt J, Howard L, Syndikus I. 
 ASTRO 2016 
 
